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Preface 
 
My PhD was devoted to the study of the possible relationship of pain and Alzheimer 
disease (AD) using the analgesic Kyotorphin as a bridge. 
I became very interested in the area of chronic pain still on the faculty of Medicine. 
Later, I started my hospital rotations and this area changed from a theoretical to a 
practical subject, since pain is one of the main complaints that drive patients to 
hospitals. The study and treatment of chronic pain were some of the reasons why I 
chose the residency in Anesthesiology.  
I always found laboratory work and basic research fascinating, so the possibility of 
working at the Institute of Molecular Medicine - Faculty of Medicine was a great 
opportunity to develop my PhD and link basic and clinical research. 
I was fortunate enough to know Professor Miguel Castanho and his group, who 
proposed me a translational project involving the study of the peptide kyotorphin in 
the relation between pain and neurodegeneration. 
This project conducted to pain evaluation in patients with the diagnosis of Alzheimer 
disease using validated scales. Later, the quantification of kyotorphin in the cerebro-
spinal fluid of AD patients was determined. To achieve this, we collaborated with the 
laboratory of metabolopathies of the Hospital of Santiago Compostela, with the 
development of mass spectrometry techniques to detect KTP in biological fluids. The 
results were promising enough to advance further to the testing of kyotorphin derived 
peptides in an animal model of Alzheimer disease. 
During this path I worked with people specialized in the various fields the work 
involved, namely pain, neurosciences and biochemistry, which was a very enriching 
experience. 
 
My PhD work originated the following papers, most of them already published:  
 
I. Biomedical applications of di- and tri-peptides 
Santos SM, Torcato I, Castanho M 
Biopolymeres Peptide Science (2012) Volume 98, Issue 4, pages 288–293 (DOI: 
10.1002/bip.22067) 
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II. The use of visual analogue scales to compare pain between patients with Alzheimer’ 
disease and patients without any known neurodegenerative disease and their 
caregivers.  
Santos SM, Castanho M  
Am J Alzheimer’s Dis and Other Demen (2013) (DOI: 10.1177/1533317513517046) 
[Epub ahead of print] 
 
III. Neuropeptide kyotorphin (tyrosyl-arginine) has decreased levels in the cerebro-
spinal fluid of Alzheimer’s disease patients: potential diagnostic and pharmacological 
implications. 
Santos SM; Garcia-Nimo L, Sá Santos S, Tavares I, Cocho JA,  Castanho MARB.  
Frontiers in Aging Neuroscience (2013) Volume 5, Article 68 (DOI: 
10.3389/fnagi.2013.00068) 
 
IV. Amidated and ibuprofen conjugated kyotorphins are neuroprotective in the 
hippocampus and improve spatial working memory after bilateral carotid occlusion in 
female rats 
In preparation 
 
V. Side effects of analgesic Kyotorphin derivatives: advantages over clinical opioid 
drugs 
Ribeiro MM, Santos SS, Sousa DS, Oliveira M, Santos SM, Heras M, Bardaji E, Tavares I, 
Castanho M 
Amino Acids (2013) Volume 45, Issue 1, pages 171-178 (DOI: 10.1007/s00726-013-
1484-2) 
 
 
This dissertation is divided into 5 sections. In the first section the reader can find an 
introduction to the complexity of pain physiological pathways and to the complexity of 
endogenous opioid peptides as well as the potential of peptides to treat pain 
conditions, with a particular focus on kyotorphin. In this chapter the reader can also 
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find a brief approach to the pathophysiology and actual therapeutic options for 
Alzheimer´s disease.  
In sections 2 and 3 different studies carried out within the context of this thesis are 
presented, in the form of scientific papers. A general conclusion of all results is 
presented in Chapter 4. There were two key papers seminal to this work: the first 
(Ribeiro, 2011a) is a paper on the subject of the inhibition of nociceptive responses 
after systemic administration of amidated kyotorphin and the second (Ribeiro, 2011b) 
is a paper showing that the chemical conjugation of Kyotorphin and Ibuprofen 
enhances brain targeting and analgesia. Both papers originated from the same 
investigation group and support the later work, condensed in this dissertation.  
  
In this dissertation, two distinct referencing methods were followed. The References 
cited along the thesis (excluding articles) are listed in section 5, sorted alphabetically 
by first author’s last name. Within each paper published, the format of the References 
cited comply with the guidelines defined by the respective journal and are listed at the 
end of the articles. 
  
VII 
 
Abbreviations and Symbols 
 
 
 
-OR – delta opioid receptor 
-OR – kappa opioid receptor 
µ-OR – mu opioid receptor 
BBB – blood-brain barrier 
CNS – central nervous system 
i.c.v. - intracerebroventricular 
i.p. – intra-peritoneal 
IASP – International Association for the Study of Pain 
Ib – ibuprofen 
IbKTP – kyotorphin linked to ibuprofen 
IbKTP-NH2 – kyotorphin-amide linked to ibuprofen 
KTP – kyotorphin 
KTP-NH2 – kyotorphin amide 
KTPr – kyotorphin specific receptor 
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NOP – nociceptin/orphanin receptor 
NSAIDs – non-steroidal anti-inflammatory drugs 
DRG - dorsal root ganglia 
AD – Alzheimer´s Disease 
Ach – Acetylcholine 
MCI - mild cognitive impairment  
CSF - cerebrospinal fluid  
 
 
 
 
 
VIII 
 
Resumo 
O aumento da esperança média de vida tem provocado um aumento na incidência de 
doenças relacionadas com o processo de envelhecimento. Entre estas, destacam-se as 
doenças neurodegenerativas, nomeadamente a Doença de Alzheimer (DA), e outras 
entidades associadas a fenómenos de dor crónica.  
A possível correlação entre duas entidades – dor e doença de Alzheimer - com uma 
carga epidemiológica tão grande afigura-se um passo relevante. A dor, hoje 
considerada como 5º sinal vital e presente numa larga camada da população, 
encontra-se ainda de grande modo sub-tratada, sendo necessários novos fármacos 
que actuem em alvos diferentes e que, ao mesmo tempo, tenham uma menor 
panóplia de efeitos adversos. Por outro lado, a doença de Alzheimer é uma patologia 
largamente disseminada na nossa população, afectando primariamente as camadas 
idosas mas também e cada vez mais uma população mais jovem. O desconhecimento, 
a complexidade dos processos bioquímicos e fisiológicos envolvidos e a progressiva 
perda cognitiva dos pacientes resultam em terapêuticas ainda pouco eficazes. O 
aumento do conhecimento científico sobre a doença aos vários níveis é a via 
obrigatória para assegurar uma melhoria na prestação de cuidados de Saúde 
apropriados e aumentar a possibilidade de intervir em estadios precoces da doença, 
inclusivamente ao nível da prevenção e diagnóstico. As consequências do diagnóstico e 
do evoluir desta patologia são bem conhecidas: alteração do ambiente 
familiar/emocional do doente e sobrecarga para os prestadores de cuidados. Por isso, 
uma estratégia visando a correlação entre estas duas entidades e possíveis alvos 
terapêuticos comuns a um único agente farmacológico é promissora. 
Como já foi referido, o projecto proposto foca dois temas de extrema importância 
clínica e forte impacto social: doença de Alzheimer e Dor. O aspecto mais inovador 
prende-se com a hipótese de ambos os problemas poderem estar correlacionados e 
poderem, portanto, ser abordados numa abordagem terapêutica única. Esta hipótese 
é sustentada por trabalho laboratorial in vitro, partindo-se agora para uma outra fase, 
com experimentação animal em modelos de doenças e investigação clínica. 
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Neste trabalho pretendeu-se avaliar uma molécula, a quiotorfina, como um elo 
molecular de ligação dos mecanismos envolvidos nos dois casos.  
A Quiotorfina (KTP), descoberta em 1979, foi descrita como um dipéptido analgésico 
endógeno actuante no encéfalo. Com uma actividade analgésica cerca de 4 vezes 
superior a outros péptidos endógenos como a met-encefalina, este dipéptido 
apresenta características muito interessantes e pensa-se que actua através de 
mecanismos opióides. Moléculas analgésicas derivadas da quiotorfina tinham sido 
previamente testadas para o seu efeito simultaneamente analgésico in vivo, em 
animais modelo, e neuroprotector in vitro, após admnistração periférica.  
O presente projecto traz estes resultados até à investigação clínica e os seus principais 
objectivos foram: 1) perceber se existe uma correlação entre doença de Alzheimer e 
Dor, 2) a hipótese de péptidos analgésicos derivados da quiotorfina serem fármacos 
capazes de neuromodulação e 3) o potencial da quiotorfina como marcador molecular 
na doença de Alzheimer. 
Para atingir esses objectivos, combinou-se investigação clínica e básica, utilizando 
técnicas diversificadas como questionários e escalas de dor, técnicas analíticas 
sofisticadas de espectrometria de massa e experimentação animal. 
Numa primeira fase avaliou-se a percepção dolorosa em doentes com Alzheimer e 
seus cuidadores, através da utilização de escalas de dor validadas. Este estudo levou à 
conclusão de que, em consonância com os achados na literatura, a dor em doentes 
com Alzheimer é frequentemente sub-avaliada e consequentemente, subtratada. Este 
fenómeno acontece porque provavelmente estes doentes são incapazes de valorizar 
e/ou expressar o seu sofrimento, mesmo em estadios moderados da doença. 
A investigação clínica envolveu outro componente: a colheita de amostras de líquido 
céfalo-raquidiano em doentes com DA para determinação dos níveis de quiotorfina, e 
sua comparação com indivíduos sem doenças neurodegenerativas conhecidas; 
verificou-se que os níveis de quiotorfina, por si um neuropéptido endógeno, diminuem 
com a progressão da doença de Alzheimer. 
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Este achado abre novas possibilidades, nomeadamente o uso da quiotorfina como 
possível marcador de neurodegenerescência, e que este neuropéptido tenha acções 
neuromoduladoras. 
Posteriormente estudou-se o efeito de neuropéptidos derivados da quiotorfina 
capazes de atravessar a barreira hemáto-encefálica - IbKTP-NH2 e KTP-NH2 - em 
modelos animais, com dois objectivos: perceber se os fármacos apresentavam efeitos 
secundários significativos por comparação a opióides de referência usados na prática 
clínica, e qual o seu efeito num modelo animal de neurodegenerescência. 
Estes derivados amidados KTP-NH2 e IbKTP-NH2, ao contrário da morfina e do tramadol 
(dois fármacos utilizados na prática clínica), não provocaram os principais efeitos 
secundários associados aos opióides, o que constitui mais uma indicação de que os 
mecanismos de acção destes péptidos e dos opióides não coincide totalmente. Por 
outro lado, os animais modelo de neurodegenerescência aos quais estes compostos 
foram administrados de forma crónica  revelaram uma melhoria no padrão 
comportamental relativamente aos animais com lesões neurológicas aos quais não 
tinha sido administrado nenhum dos compostos. 
Globalmente os nossos resultados apontam a quiotorfina como um possível 
biomarcador na doença de Alzheimer, e os seus derivados IbKTP-NH2 e KTP-NH2, 
capazes de neuromodulação/neuroprotecção, além moléculas analgésicas eficazes 
com efeitos secundários reduzidos. 
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Abstract 
The increased lifespan has brought about an increase in the incidence of diseases 
related to the aging process. Among these, there are the neurodegenerative diseases, 
including Alzheimer's disease (AD) and other entities associated with the phenomena 
of chronic pain. 
The possible correlation between two entities - pain and Alzheimer's disease - with 
such a large epidemiological burden is of enormous importance. Nowadays pain is 
considered the fifth vital sign and is highly prevalent, still largely under-treated. New 
drugs acting on different targets with a smaller range of adverse effects are needed. 
Moreover, Alzheimer's disease is widely spread in our population, primarily affecting 
the elderly but also a younger population. The ignorance of the complexity of the 
biochemical and physiological processes involved and progressive cognitive 
impairment of patients still result in ineffective treatment. The increase in scientific 
knowledge about the disease at various levels is mandatory in order to ensure an 
improvement in the provision of appropriate health care and the chance of intervening 
in the early stages of the disease, including at the level of prevention and diagnosis. 
The consequences of diagnosis and evolution of this pathology are well known: change 
in family / emotional environment of the patient and burden on caregivers. Therefore, 
a strategy for the correlation between these two entities and possible common 
therapeutic targets involving a single pharmacological agent is promising. 
As already mentioned, this project focuses on two issues of utmost clinical importance 
and strong social impact: Pain and Alzheimer's disease. The most innovative aspect 
relates to the hypothesis that both problems can be related and may, therefore, be 
addressed in a single therapeutic approach. This hypothesis is supported by previous 
experimental work in vitro, evolving now to another phase, with animal 
experimentation in disease models and clinical research. 
This thesis intended to evaluate a molecule, kyotorphin, as a molecular link in the 
mechanisms involved in both cases. Kyotorphin (KTP), discovered in 1979, was 
described as an endogenous analgesic dipeptide actuating in the brain. With an 
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analgesic activity about 4 times higher than other endogenous peptides such as met-
enkephalin, this dipeptide has very interesting features and is thought to act via opioid 
mechanisms. Analgesic derived molecules of kyotorphin had previously been tested for 
their analgesic effect in vivo in animal models and for in vitro neuroprotective effects 
after peripheral administration. 
This project brings these results to clinical research and its main objectives were: 1) to 
understand if there is a correlation between Alzheimer's disease and pain, 2) if 
analgesic peptides derived from kyotorphin are capable of neuromodulation and 3) 
evaluate kyotorphin as a potential molecular marker in Alzheimer's disease. To achieve 
these objectives, clinical and basic research were combined using diverse techniques 
such as questionnaires and pain scales, sophisticated analytical techniques of mass 
spectrometry and animal experimentation.  
In a first stage we assessed pain perception in Alzheimer patients and their caregivers, 
using validated pain scales. This study concluded that, in line with the findings in the 
literature, pain in Alzheimer patients is often under-evaluated and therefore 
undertreated. This phenomenon probably occurs because these patients are unable to 
value and/or express their suffering, even in moderate stages of the disease. Clinical 
research involved another component: the collection of cerebrospinal fluid samples of 
patients with AD for determination of Kyotorphin levels and its comparison with 
individuals without known neurodegenerative diseases; it was found that the levels of 
kyotorphin , a neuropeptide endogenous per se, decreases with the progression of 
Alzheimer's disease. This finding opens new possibilities, including the use of 
kyotorphin as a possible marker of neurodegenerescence and that this neuropeptide 
has neuromodulatory actions. Subsequently, we studied the effect of neuropeptide 
kyotorphin derivatives capable of crossing the blood brain barrier - IbKTP-NH2 e KTP-
NH2 – in animal models with two objectives: realize if these drugs showed significant 
side effects compared to reference opioids used in clinical practice, and what were 
their effects in an animal model of neurodegenerescence. These amidated derivatives 
IbKTP-NH2 e KTP-NH2, unlike morphine and tramadol (two largely used drugs in 
clinical practice), caused no major side effects associated with opioids, which is a 
further indication that the mechanism of action of these peptides and opioids not fully 
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coincide. On the other hand, the neurodegeneration animal model to which these 
compounds were chronically administered revealed an improvement in the behavioral 
pattern in comparison with animals with neurological lesions to which none of the 
compounds had been administered. 
Overall, our results indicate kyotorphin as a possible biomarker for Alzheimer's 
disease, and its derivatives IbKTP-NH2 and KTP-NH2 capable of 
neuromodulation/neuroprotection, in addition to effective analgesic molecules with 
reduced side effects. 
  
XIV 
 
Keywords 
 
Neuropeptides 
 
Kyotorphin 
 
Alzheimer 
 
Neurodegeneration 
 
Pain 
 
  
XV 
 
Contents 
Acknowledgments ...................................................................................................................I 
Preface .................................................................................................................................. IV 
Abbreviations and Symbols ................................................................................................ VII 
Resumo ............................................................................................................................... VIII 
Abstract ................................................................................................................................. XI 
Keywords ............................................................................................................................ XIV 
Contents ............................................................................................................................... XV 
Introduction ........................................................................................................................ 18 
1. Pain........................................................................................................................... 20 
1.1 Epidemiology And Etiology .............................................................................. 20 
1.2 Pathophysiology ............................................................................................... 22 
2. Alzheimer´s Disease ................................................................................................ 33 
2.1 Introduction ...................................................................................................... 33 
2.2 Epidemiology and Genetics .............................................................................. 33 
2.3 Neuropathology and Pathophysiology ........................................................... 34 
2.4 Presentation and Natural History ................................................................... 35 
2.5 Clinical, pathological and radiological evaluation.......................................... 36 
2.6 Treatment ......................................................................................................... 38 
2.7 Conclusion ........................................................................................................ 39 
3. Kyotorphin ............................................................................................................... 41 
4. Peptides as Drugs Candidates ................................................................................ 45 
ARTICLE 1 
Biomedical Applications of di and tri-peptides ............................................................. 48 
5. Main Goals of the Project ....................................................................................... 55 
Pain in Alzheimer´s Disease ............................................................................................... 57 
ARTICLE 2 
The Use of Visual Analog Scales to Compare Pain between Patients with Alzheimer’s 
Disease and Patients Without Any Known Neurodegenerative Disease and Their 
Caregivers ........................................................................................................................ 59 
Kyotorphin and derivatives in Alzheimer´s Disease  ....................................................... 73 
XVI 
 
ARTICLE 3 
Neuropeptide kyotorphin (tyrosyl-arginine) has decreased levels in the cerebro-
spinal ﬂuid of Alzheimer’s disease patients: potential diagnostic and pharmacological 
implications ...................................................................................................................... 75 
Supplementary Material to Section 3 (Article 3) .......................................................... 85 
ARTICLE 4 
Amidated and ibuprofen-conjugated kyotorphins are neuroprotective in the 
hippocampus and improve spatial working memory after bilateral carotid occlusion 
in female rats ................................................................................................................... 87 
ARTICLE 5 
Side-effects of Analgesic Kyotorphin derivatives: advantages over clinical opioid 
drugs ............................................................................................................................... 116 
Final Conclusions .............................................................................................................. 126 
References ......................................................................................................................... 132 
 
 
  
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 1 
  
Introduction 
19 
 
 
 
 
  
20 
 
1. Pain 
 
Pain is defined by the International Association for the Study of Pain as “an unpleasant 
sensory and emotional experience related to actual or potential tissue damage, or 
described in terms of such damage.” Pain is an unpleasant subjective experience that is 
the net result of a complex interaction of the ascending and descending nervous 
systems involving organic chemistry, physiological, psychological, and neocortical 
processes. Pain can have an effect on all areas of a person’s life, including sleep, 
thought, emotion, and activities of daily living. Since there are not any reliable, 
objective markers for pain, the patients and their caregivers are the sole ones to 
describe the intensity and quality of their pain (Porter, 2008). 
Pain is the most common symptom prompting patients to search for medical attention 
and is reported by over 80% of people who visit their primary care provider (Mularski, 
2006).  Despite the frequency of pain symptoms, individuals often do not get 
satisfactory relief of pain which has led to initiatives in health care to designate pain as 
the fifth vital sign, therefore making pain assessment equally vital as getting a patient’s 
temperature, pulse, pressure level, and respiratory rate (Pasero, 1997). 
 
 
1.1 Epidemiology And Etiology 
Prevalence of Pain 
 
Most people experience pain at some time in their lives, and pain is a symptom of a 
variety of diseases. For some, pain may be mild to moderate, intermittent, easily 
managed, and have minimal effect on daily activities. For others, pain may be chronic, 
severe or disabling, all consuming, and be treatment resistant. Thus, identifying the 
exact prevalence of pain is a difficult task. According to the American Pain Foundation, 
more than 50 million people in the United States of America (U.S.A.) suffer from 
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chronic pain and an additional 25 million experience acute pain from injury or surgery.   
About 20% of adults, mostly women and the elderly, experience chronic pain such as 
back pain, headache, and joint pain (Gallagher, 2006). Overall, older people are more 
likely to have painful pathology due to the increased incidence of chronic medical 
conditions, particularly of rheumatology (osteoporosis, osteoarthritis) and oncology 
fields; pain represents 25-50% of the complaints in outpatient and 45-80% of the 
complaints in institutionalized patients (Scherder, 2008). Studies suggest that 25% to 
50% of community-dwelling elderly suffer pain. Pain is also quite common among 
nursing home residents: it is estimated that pain in 45% to 80% of nursing home 
patients contributes to functional impairment and a decreased quality of life (Landi, 
2001; Reyes-Gibby, 2002). 
 
Prevalence rates for a variety of different types of pain have been described. The 
annual incidence of moderate-intensity back pain is 10% to 15% of the adult 
population with a point prevalence of 15% to 30% (Andersson, 1999). Cancer is 
commonly associated with both acute and chronic pain, and about 70% of those 
diagnosed with cancer will experience significant pain (Burton, 2007). 
 
The prevalence of neuropathic pain is largely unknown because of the lack of 
epidemiological studies. Current estimates suggest that it affects approximately 4 
million people in the USA each year. It is associated with many diseases, including 
diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency 
virus-related disorders, and chronic radiculopathy.  Central neuropathic pain is 
estimated to occur in 2% to 8% of all stroke patients (Chen, 2004).  
 
The impact of pain on economies is enormous, with some studies showing that the 
cost of back pain alone is equivalent to more than a fifth of one country's total health 
expenditure and 1.5% of its annual gross domestic product, or that it represents three-
times the total cost of all types of cancer (Phillips, 2006).  Every year, pain costs 34 
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billion € in Europe and in the USA 80 billion € are spent in direct health care 
expenditure and lost work time (Melnikova, 2010). 
 
Despite the growing emphasis on pain management, pain often remains undertreated 
and continues to be a problem in hospitals, long-term care facilities, and the 
community. In one series of reports, 50% of seriously ill hospitalized patients reported 
pain; however, 15% were dissatisfied with pain control, and some remained in pain 
after hospitalization (Desbiens 1996; Desbiens 2006). 
 
 
1.2 Pathophysiology 
 
The pathophysiology of pain involves a complex array of neural networks in the brain 
that are acted on by afferent stimuli to produce the experience we know as pain. In 
acute pain, this modulation is short-lived, but in some situations, the changes may 
persist, and chronic pain develops (Loeser, 1999; Woolf, 2004). 
 
1.2.1 Types of Pain 
 
Classification of Pain 
 
Pain has always been described as a symptom. However, recent advances in the 
understanding of neural mechanisms have demonstrated that unrelieved pain may 
lead to changes in the nervous system known as neural plasticity. Since these changes 
reflect a process that influences a physiologic response, pain, particularly chronic pain, 
may be considered a disease itself. 
A primary distinction lies in its duration and divides pain in acute (transient) and 
chronic (persistent). Chronic pain has been defined temporally as a pain that persists 
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for more than 3 to 6 months or that remains in the absence of its causes (Sandkuller, 
2009). Acute pain is also referred to as adaptive pain since it serves to protect the 
individual from further injury or promote healing. However, chronic pain has been 
called maladaptive, a pathologic function of the nervous system or pain as a disease. 
 
Several distinct types of pain have been described: nociceptive, inflammatory, 
neuropathic, and functional (Costigan, 2009). Nociceptive pain is a transient pain in 
response to a noxious stimulus at nociceptors that are located in cutaneous tissue, 
bone, muscle, connective tissue, vessels, and viscera. Nociceptors may be classified as 
thermal, chemical, or mechanical. The nociceptive system extends from the receptors 
in the periphery to the spinal cord, brain stem, and to the cerebral cortex where pain 
sensation is perceived. This system is a key physiologic function that prevents further 
tissue damage due to the body’s autonomic withdrawal reflex. When tissue damage 
occurs despite the nociceptive defense system, inflammatory pain ensues. The body 
now changes focus from protecting against painful stimuli to protecting the injured 
tissue. The inflammatory response contributes to pain hypersensitivity that serves to 
prevent contact or movement of the injured part until healing is complete, thus 
reducing further damage (Passero, 1999). 
 
Neuropathic pain, caused by dysfunction or damage to the peripheral or central 
nervous system, is typified by the symptoms described by patients with painful 
diabetic neuropathy, post-herpetic neuralgia and central poststroke pain. All these 
conditions are more common in the elderly. Neuropathic pain has long been 
recognized as one of the more difficult types of pain to treat; however, with the 
current emphasis on providing a multidisciplinary assessment and approach to 
management, more patients will be offered relief of their symptoms and an improved 
quality of life (Ahmad, 2002). 
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Functional pain, a relatively newer concept, is pain sensitivity due to an abnormal 
processing or function of the central nervous system in response to normal stimuli. 
Several conditions considered to have this abnormal sensitivity or hyperresponsiveness 
include fibromyalgia and irritable bowel syndrome (Bennett, 1998).  
 
 
1.2.2 Mechanisms of Pain 
 
Pain Transmission 
 
The mechanisms of nociceptive pain are well-defined and provide a foundation for the 
understanding of other types of pain. 
 
Nociception is the process by which intense thermal, mechanical or chemical stimuli 
are detected by a subpopulation of peripheral nerve fibers, called nociceptors 
(Basbaum and Jessell, 2000). The cell bodies of nociceptors are located in the dorsal 
root ganglia (DRG) for the body and the trigeminal ganglion for the face, and have both 
a peripheral and central axonal branch that innervates their target organ and the 
spinal cord, respectively. Nociceptors are excited only when stimulus intensities reach 
the noxious range, suggesting that they possess biophysical and molecular properties 
that enable them to selectively detect and respond to potentially injurious stimuli.  
Nociceptors can be divided into two general types: A-fibers and C-fibers. 
A-fiber nociceptors have lightly myelinated axons, conduct action potentials rapidly, 
and have medium to large-diameter cell bodies. A-fibers mediate the fast, pricking 
quality of pain. These include medium diameter myelinated (Aδ) afferents that 
mediate acute, well-localized “first” or fast pain. These myelinated afferents differ 
considerably from the larger diameter and rapidly conducting Aβ fibers that respond to 
innocuous mechanical stimulation (i.e. light touch). Electrophysiological studies have 
further subdivided Aδ nociceptors into two main classes, type I (HTM: high threshold 
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mechanical nociceptors - respond to both mechanical and chemical stimuli, but have 
relatively high heat thresholds - >50ºC) and type II (much lower heat threshold, but a 
very high mechanical threshold) (Basbaum, 2009). 
 
C-fibers have unmyelinated axons, conduct action potentials slowly, and have small-
diameter cell bodies. C-fibers mediate the slower, burning quality of pain. C-fibers 
comprise around 70% of all nociceptors. Two classes of C-fibers have been identified. 
One class contains a variety of neuropeptides, including substance P and calcitonin 
gene-related peptide, and expresses trkA receptors, the high-affinity receptor for 
nerve growth factor (Averill, 1995). These neurons project to the outermost region of 
the spinal dorsal horn (lamina I and outer lamina II) and terminate largely on spinal 
neurons that project to higher-order pain centers in the brain (Stucky, 2001). The other 
class contains few neuropeptides but expresses a surface carbohydrate group that 
selectively binds to a plant lectin called isolectin B4 (IB4). This subpopulation of neurons 
is supported by glial-derived neurotrophic factor during early postnatal development 
(Molliver, 1997). The IB4-binding neurons project to a different region of the spinal 
dorsal horn (inner lamina II) that contains primarily local spinal interneurons. 
Important questions are whether these two types of nociceptors have different 
functional responses to painful stimuli and whether they have distinct roles in specific 
types of pain. 
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Figure 1 – Nociceptors diversity. Nociceptors can be distinguished in A, A and C fibers that differ in 
physiological and functional aspects to detect and conduct different types of pain. Mechanical, thermal  
and chemical stimuli are perceived and transduced. 
 
 
Neurobiological research in the pain field provided solid information regarding the 
transmission and modulation of nociceptive information from the periphery to the 
brain, where a pain sensation is produced (Figure 2 and 3). Nociceptive signals are 
conveyed by primary afferent fibers from peripheral organs, like the bladder or 
muscles, to the spinal cord. This is the first relay station involved in the modulation of 
nociceptive information, namely by local inhibitory interneurons that use opioid 
peptides or aminoacids (γ-amminobutiric acid-GABA and glycine). Nociceptive 
information is then transmitted supraspinally, namely to the thalamus, and to several 
brainstem areas, where additional modulation of the nociceptive signal occurs. The 
thalamo-cortical pathway ensures that the nociceptive information reaches the 
somato‐sensory and prefrontal cortices, where the nociceptive signal is finally 
perceived as a pain sensation. Some brain areas which directly or indirectly receive 
nociceptive information from the spinal cord are also involved in descending pain 
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modulation (Tavares, 2013). The brainstem concentrates all regions directly 
modulating the ascending nociceptive transmission from the spinal dorsal horn and 
mediates the pain control orders triggered by the forebrain areas responsible for 
coordination of the final pain perception. Moreover, the brainstem (and the medial 
thalamus) is also the main recipient of the spinal nociceptive information concerning 
the motivational-affective dimension of pain (Almeida, 2006). 
Both inhibition and facilitation may occur and chronic pain may derive from a 
reduction of the former and enhancement of the latter (Tavares, 2013).  
 
 
Figure 2 – Pain signaling and pathways. Nociceptors are activated in the periphery by noxious stimuli  
and send afferent information to the dorsal horn of the spinal cord. a) Synaptic transmission in the 
dorsal horn is modulated by several neurochemicals. b) Peripheral mediators of pain transduction after 
tissue injury. Inflammation leads to the release of numerous chemicals from mast cells, macrophages 
and injured cells that act directly or indirectly to alter the sensitivity of receptors and ion channels on 
peripheral nerve terminals (from Woodcock, 2007). 
28 
 
 
Figure 3 - Schematic diagram of pain pathways involved in pain transmission and modulation. 
Nociceptive information is transmitted from the periphery to the spinal dorsal horn by primary sensory 
neurons. At the spinal level, these neurons transmit nociceptive information to second order neurons 
(Ascending pathways) through the release of neurotransmitters like the excitatory amino acids (EAA) 
glutamate and aspartate, calcitonin gene-related peptide (CGRP), substance P (SP) galanin (Gal) and 
neuropeptide Y (NPY). In the brain, the nociceptive information is then perceived as a pain sensation. 
The transmission of nociceptive information at the spinal level is modulated by interneurons (mainly 
inhibitory) through the release of opioid peptides and GABA and also by supraspinal descending neurons 
(descending pathways) through the release of serotonin (5-HT) and noradrenaline (NA). Descending 
pathways may inhibit or enhance nociceptive transmission from the spinal cord (from Tavares, 2013). 
 
 
1.2.3 Pain Modulation 
Understanding the central modulation of pain perception was greatly advanced by the 
finding that electrical or pharmacological stimulation of certain regions of the midbrain 
produces relief of pain. This analgesic effect arises from activation of descending pain-
modulating pathways that project, via the medulla, to neurons in the dorsal horn—
particularly in Rexed's lamina II—that control the ascending information in the 
nociceptive system. The major brainstem regions that produce this effect are located 
in poorly defined nuclei in the periaqueductal gray matter and the rostral medulla. 
Electrical stimulation at each of these sites in experimental animals not only produces 
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analgesia by behavioral criteria, but also demonstrably inhibits the activity of 
nociceptive projection neurons in the dorsal horn of the spinal cord. 
A quite ordinary example of the modulation of painful stimuli is the ability to reduce 
the sensation of sharp pain by activating low-threshold mechanoreceptors: a reaction 
is to vigorously rub the site of an injury for a minute or two. Even though further 
investigation led to modification of some of the original propositions in Melzack and 
Wall's gate theory of pain, the idea stimulated a great deal of work on pain 
modulation: that the flow of nociceptive information through the spinal cord is 
modulated by concomitant activation of the large myelinated fibers associated with 
low-threshold mechanoreceptors. 
Pain modulation may result through several other complex processes. One of the most 
exciting advances in this long-standing effort has been the discovery of endogenous 
opioids. For centuries it had been apparent that opium derivatives such as morphine 
are powerful analgesics—indeed, they remain a mainstay of analgesic therapy today. 
Modern animal studies have shown that a variety of brain regions are susceptible to 
the action of opiate drugs, particularly—and significantly—the periaqueductal gray 
matter and the rostral ventral medulla. There are, in addition, opiate-sensitive regions 
at the level of the spinal cord. In other words, the areas that produce analgesia when 
stimulated are also responsive to exogenously administered opiates. It seems likely, 
then, that opiate drugs act at most or all of the sites shown in Figure 4 in producing 
their dramatic pain-relieving effects (Purves D. et al, 2001b). 
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Figure 4 - The descending systems that modulate the transmission of ascending pain signals. These 
modulatory systems originate in the somatic sensory cortex, the hypothalamus, the periaqueductal gray 
matter of the midbrain, the raphe nuclei, and other nuclei of the rostral ventral medulla. Complex 
modulatory effects occur at each of these sites, as well as in the dorsal horn (from: Purves et al, 2001a). 
 
The analgesic action of opiates implied the existence of specific brain and spinal cord 
receptors for these drugs long before the receptors were actually found during the 
1960s and 1970s (Table 1). Since such receptors are unlikely to exist for the purpose of 
responding to the administration of opium and its derivatives, the conviction grew that 
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there must be endogenous compounds for which these receptors had evolved. Several 
categories of endogenous opioids have now been isolated from the brain and 
intensively studied (Table 2). These agents are found in the same regions that are 
involved in the modulation of nociceptive afferents, although each of the families of 
endogenous opioid peptides has a somewhat different distribution. All three of the 
major groups (enkephalins, endorphins, and dynorphins) are present in the 
periaqueductal gray matter. The enkephalins and dynorphins have also been found in 
the rostral ventral medulla and in the spinal cord regions involved in the modulation of 
pain (Purves D. et al, 2001b).  
 
Table 1 – Opioid receptors: location and response on activation 
Receptor CNS location Response on activation 
µ 
Brain (laminae III and IV 
of the cortex, thalamus, 
periaqueductal gray), spinal 
cord (substantia gelatinosa) 
µ 1: supraspinal analgesia, physical 
dependence; µ 2: respiratory 
depression, miosis, euphoria, 
reduced gastrointestinal motility, 
physical dependence 
 
Brain (hypothalamus, 
periaqueductal gray, 
claustrum), spinal cord 
(substantia gelatinosa) 
Spinal analgesia, sedation, miosis, 
inhibition of antidiuretic hormone 
release 
 
Brain (pontine nucleus, 
amygdala, olfactory bulbs, 
deep cortex) 
Analgesia, euphoria, physical 
dependence 
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Table 2 – Classes of opioid peptides with representative examples of peptides, their sequence and 
preference binding to opioid receptors. Orange and blue colours highlight the different amino acid 
residues inside each class. 
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2. Alzheimer Disease  
2.1 Introduction 
Alzheimer's disease (AD) was described it in the early 20th century. It has rapidly 
emerged as a major public health issue throughout the world. It is estimated to be by 
far the most common form of dementia in the United States, currently afflicting over 5 
million people, mainly elderly individuals, with an associated healthcare cost in excess 
of US$100 billion annually (Alzheimer´s Association, 2009). It is characterized most 
notably by memory loss, and increasing age is its single most important risk factor 
(Bird, 2007). Memory loss and dementia, in general, are progressive and irreversible, 
though the rate of progression is highly variable and impossible to predict (Bird, 2007). 
 
2.2 Epidemiology and Genetics 
Advancing age is the single most major risk factor for AD, with the prevalence doubling 
every 5 years between the ages of 65 and 95 years and increasing from 2% at 65 years 
of age to 40% at over 85 years of age (Gao, 1998). While people do experience minor 
changes in their memory and thinking as they age, these changes do not affect daily 
functioning or the ability to live independently. Although the illness has been reported 
to occur in exceedingly rare patients in their 20s and 30s, onset of clinical symptoms in 
this illness is uncommon until the 50s (Duijn, 1991). The second major risk factor for 
AD is family history, with a threefold to fourfold higher risk among individuals having a 
single first-degree relative with AD and a nearly eightfold higher risk among individuals 
with two or more first-degree relatives with AD (Duijn, 1991). In contrast late-onset 
AD, early-onset AD is relatively rare, affecting only 5% of AD patients and developing in 
individuals of 30-60 years of age (Duijn, 1991). Some cases of early-onset AD, termed 
familial AD, are inherited in an autosomal dominant manner, with genetic mutations 
on chromosomes 21, 14 and 1, resulting in the formation of abnormal precursor 
proteins, presenilin 1 (PS-1) and presenilin 2 (PS-2). The presenilins have been found to 
operate in a complex that acts functionally as γ-secretase (Brunkan, 2005). Specifically, 
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a few dozen families have mutations in the amyloid precursor protein (APP) gene, 
usually in the region of the gene that codes for the β-amyloid proteins (Goedert, 2006). 
Increased levels of β-amyloid have been found in AD patients with PS-1 or PS-2 
mutations (Scheuner, 1996). Apolipoprotein E (ApoE) gene status on chromosome 19 
appears to be a major genetic susceptibility risk factor for the development of typical 
late-onset AD (Tsai, 1994). Other possible risk factors for AD include gender, 
education, head trauma, memory deficit with severity of any extent, and small 
hippocampal volume. The very large Women's Health Initiative Memory Study of 
estrogen in elderly women has shown that estrogen replacement may increase, rather  
than decrease, the risk for AD (Rapp, 2003). Several studies indicate that lack of 
education is also a risk factor for AD, or alternatively, education may impart a 
"cognitive reserve" that delays the onset of clinical manifestations of AD (Schmand, 
1997). Studies have been muddled by wide differences in reported series in the criteria 
applied to define significant head trauma history. Further, ApoE e4 patients have been 
demonstrated to recover less well from head trauma, so the greater manifestations of 
trauma may be a pseudo-marker for ApoE e4 inheritance, which is a risk factor for AD 
(Jellinger, 2004). A wealth of data from various studies has suggested that a strong 
association between the metabolic syndrome and vascular risk factors appears to 
increase the risk for AD (Martins, 2006). Specifically, diabetes mellitus, insulin 
resistance, high cholesterol, hypertension, reduced exercise, and obesity are all risk 
factors with some association for AD (Sidera, 2005; Moreira, 2007).  
 
2.3 Neuropathology and Pathophysiology 
 
Dementia is causally associated with disruption of cerebral neuronal circuits, with the 
amount and location of neuronal loss resulting in its characteristic symptomatology. 
Loss of larger neurons of the superficial cortex is a consistent feature of AD, as are 
synaptic alterations such as reduction of pre-synaptic terminal density (Cummings, 
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1998). The neurotransmitter acetylcholine (Ach) appears to be particularly important 
for memory, and loss of cholinergic neurons may underlie memory loss in AD (Francis, 
1999). Anatomically, AD begins in the entorhinal cortex and progresses to the 
hippocampus and the posterior temporal and parietal neocortex, ultimately resulting 
in diffuse degeneration throughout the cerebral cortex. Grossly, AD is characterized by 
diffuse atrophy of the cerebral cortex, reflecting loss and shrinkage of neurons, with 
resulting enlargement of the ventricles. In particular, the hippocampus, part of the 
mesial temporal lobe memory system, is damaged and atrophied in AD, even at the 
earliest stages of the disease (Braque, 1991; Squirre, 1991). Microscopically, the two 
identifying features of AD are amyloid plaques and neurofibrillary tangles. In addition 
to amyloid plaques, wispy accumulations of an intracellular proteomous material 
called neurofibrillary tangles (NFTs) are present. These are the cardinal features 
originally described by Alois Alzheimer. The so-called "amyloid hypothesis", which 
ascribes a causative role in AD to abnormal amyloid processing and deposits, remains 
one of the prevailing models regarding AD causation (Hardy, 2002). As AD progresses, 
glutaminergic, noradrenergic, and serotonergic system deficiencies develop and have 
been associated with further cognitive deterioration and/or behavioral abnormalities. 
Therapeutic efforts during the last decades have largely focused on correcting these 
neurotransmitter deficits, and some modest success in improving symptoms has been 
achieved. 
 
2.4 Presentation and Natural History 
Memory loss, particularly short-term memory loss, is also the most common 
presenting symptom of AD. Longer-term memory is initially preserved but will 
eventually deteriorate as well with disease progression. This is referred to as Ribot's 
law of memory, but this is only relatively true, as it is difficult to check the accuracy of 
ancient memories (Wixted, 2004). Impairment of cognitive function that slightly 
interferes with the functions of daily living is characterized as mild cognitive 
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impairment (MCI), and many individuals with MCI will progress to AD dementia; the 
progression rate is about 12% per year, (Dujin, 1991) with faster progression in some 
subgroups, e.g. those with severe memory deficits especially when additional cognitive 
impairment is also present. Behavioral changes and psychiatric symptoms are not 
uncommon in AD, especially in the more advanced stages of the disease (Yaari, 2007). 
These include agitation, paranoia, psychosis, delusions, anxiety and insomnia. 
Frequently reported sleep disturbances include nighttime awakening, early morning 
awakening; excessive daytime sleepiness and on rare occasions, a diurnal reversal of 
sleep-wake cycle with the main sleep period occurring in the daytime (Yesavage, 
2002). AD is progressive and remains incurable and ultimately it is fatal, with death 
typically occurring 4-6 years after initial diagnosis. 
 
2.5 Clinical, pathological and radiological evaluation 
The most commonly used clinical criteria for the diagnosis of AD are those of the 
Diagnostic Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric 
Association, 1994) and those developed in 1984 by a joint task force on the National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's 
Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann, 1984). 
Normally, a neuropsychological examination explores in depth an individual's 
performance in a wide range of functional domains. Various screening tests and 
batteries have been developed during the last years, but the Mini Mental State 
Examination (MMSE) is still the most widely used, despite its weakness when it comes 
to detecting mild dementia.  
The general neurologic examination may often be normal in the demented patient 
with AD. Continuing gait problems can occur in the late stages of AD, leading to 
substantially increased risk for falls. There is currently no laboratory test to confirm the 
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diagnosis of AD. The prevailing neuropathologic criteria for AD are those promulgated 
by the National Institute on Aging (NIA) and National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) (Mirra, 1993). These criteria include 
minimal neocortical plaque densities that are age-adjusted but do not specify either 
the plaque type or the neocortical region involved. Both DSM-IV-Text Revision (DSM-
IV-TR) and NINCDS-ADRDA criteria rely heavily on history and the neurologic 
examination, and recent evidence suggests that both have fallen behind due to the 
recent dramatic advances in our scientific knowledge of AD, with reliable biomarkers 
available now being based on structural Magnetic Resonance Imaging (MRI), molecular 
imaging with Positron Emission Tomography (PET), and cerebrospinal fluid (CSF) 
analyses (DuBois, 2007). Although the revised NINCDS-ADRDA criteria remain focused 
on a clinical determination of memory impairment, they also stipulate that there must 
also be at least one abnormal biomarker among structural neuroimaging with MRI, 
molecular neuroimaging with PET, and CSF analysis of β-amyloid or Tau proteins 
(DuBois, 2007). Structural MRI in patients with AD or MCI shows atrophy in the 
entorhinal cortex and hippocampus, predictive of future cognitive decline and 
conversion to AD among individuals with MCI. It has been suggested, therefore, that 
MRI volumetry may be a useful imaging adjunct in the diagnosis of AD and may even 
exceed the diagnostic accuracy of clinical evaluation (Duara, 2008; Desikan, 2009). PET-
based imaging includes measurement of regional cerebral glucose metabolism 
(rCMRgic) using the partially metabolized glucose analog fluorine-18 (18 F)-labeled 2-
fluoro-2-deoxy-d-glucose (FDG). FDG-PET brain images in AD are characterized by 
significant regional hypometabolism. A reduction of glucose metabolism in the 
bilateral temporal, parietal and posterior cingulated region is currently the most 
commonly described diagnostic criterion for AD (Herholz, 2007). 
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2.6 Treatment 
Over a hundred years after its discovery, AD remains incurable and its progression 
inevitable, with the primary focus of treatment on mitigation of associated behavioral 
and neurologic problems. Currently no therapy has been proven to delay biological 
progression of disease. The development of drugs that will delay disease progression in 
affected individuals or primarily prevent its onset in normal older subjects remains a  
crucial, but far elusive goal (Roberson, 2006). The currently available symptomatic 
therapies for AD mildly improve defects in cognitive function, activities of daily living 
(ADLs) and global functioning, as well as delay onset of or slightly improve behavioral 
symptoms (Mangialasche, 2010). The role of family members or other caregivers is 
critical, and any benefits need to be weighed against adverse effects that may occur in 
determining an appropriate dose or deciding whether to continue therapy with a 
particular drug (Haley, 1997). Memory aids such as notebooks and posted daily 
reminders may be helpful in the early stages of the disease. The patient's home, 
especially the kitchen and bathrooms, must be made as safe as possible, and 
eventually patients must stop driving and can no longer be responsible for their 
finances and other personal affairs. 
A number of drugs have been approved for treatment of AD, albeit they are not 
curative. The current pharmacologic therapies for AD can be broadly divided into two 
categories: (1) symptomatic approaches based on enhancement of neurotransmitter 
systems and (2) neuroprotective strategies using antioxidants such as vitamin E. Many 
AD patients also are prescribed antipsychotics or antidepressants to manage 
psychiatric and behavioral symptoms, but with an apparently increased risk of 
mortality (Yaari, 2007). 
The most effective medications for AD to date are the acetylcholinesterase (AChE) 
inhibitors, which reduce the enzymatic degradation of the neurotransmitter Ach, 
deficient in the AD brain, and thus enhance the cholinergic system. The three AChE 
39 
 
inhibitors approved by the United States Food and Drug Administration (FDA) for 
treatment of AD, donepezil, galantamine and rivastigmine, have been demonstrated to 
improve cognition, function in ADL, and behavior in patients with AD in double-blind, 
placebo-controlled trials (Roberson, 2006; Geldmacher , 2004). Despite the perception 
among clinicians of limited therapeutic efficacy and cost-effectiveness of AChE 
inhibitors, this class of drugs is actually highly effective in early (i.e. mild to moderate) 
AD in terms of symptomatic control and delay of its long-term adverse effects 
(Geldmacher,2004; Geldmacher,2008). 
Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist also approved for 
use in AD and was the first drug approved for treatment of moderate to severe AD 
(Witt, 2004). Although its mechanism of action is not entirely understood, it works by 
antagonizing glutamate at the NMDA receptor, potentially improving signal 
transmission, and by preventing excess calcium to rush into the neurons with 
glutamate stimulation, and may therefore protect against toxic damage to cholinergic 
neurons. In a study, patients with moderate to severe AD treated with memantine 
alone showed significant improvement in cognitive function and ADLs in a placebo-
controlled trial (Atri, 2008). In another clinical study of patients with moderate to 
severe AD, memantine in combination with the AChE inhibitors (donepezil, 
galantamine, or rivastigmine) significantly slowed deterioration in both cognitive 
function and ADLs compared to patients treated with placebo or AChE inhibitors alone 
(Atri, 2008). 
 
2.7 Conclusion 
There is a compelling need to establish novel treatments for AD and research. AD 
therapy has been at least partly successful in terms of developing symptomatic 
treatments, but has also had several failures in terms of developing disease modifying 
therapies. While progress has been frustratingly slow in the development of effective 
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treatments for AD, understanding of its underlying biology continues to advance as 
well as the number of promising therapies. 
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3. Kyotorphin 
Kyotorphin (KTP) is an endogenous peptide, with only two amino acid residues in its 
structure: L- Tyr-L-Arg. First isolated from bovine brain in 1979 (Takagi et al., 1979), it 
was subsequently found in the brains of mice and rats (Ueda et al., 1980), guinea pigs, 
rabbits, squirrels (Svirayev V et al., 1992) and in human cerebrospinal fluid (Nishimura 
et al., 1991). KTP acts as a neurotransmitter/neuromodulator in nociceptive responses 
in the CNS (Inoue et al., 1999), having an analgesic effect approximately 4.2 fold higher 
than met-encephalin (Shiomi et al., 1981). 
Kyotorphin owes its name to the city when it was discovered – Kyoto - and to its 
morphine-like effect. The similarities with opioid molecules go beyond the activity: 
structurally, both display a phenolic ring, considered essential for the interaction of 
morphine with receptors (Figure 4). 
 
Figure 4 – Chemical structures of kyotorphin and morphine. The structural resemblances are evident: 
the phenolic hydroxyl in close proximity to a positive charge (colored in pink and purple for KTP and 
morphine, respectively). 
 
Kyotorphin is synthesized in specific brain regions where it may modulate synaptic 
transmission. Opioid systems may have mediated the effects of kyotorphin. The 
majority of research associated with kyotorphin relates to modulation of pain 
mechanisms via its ability to directly excite cortical neurons, and indirectly exert μ- and 
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δ-opioid receptors to produce potent naloxone-reversible and long-lasting analgesia 
via releasing methionine-enkephalin (Met-Enk) and β-endorpins (Takagi, 1979; 
Kawabata, 1992). However, KTP showed a wide dynamic range of bell-shaped dose-
response curves in peripheral pain experiments (Ueda, 1999). 
The exact mechanism of action of KTP remains an unsolved issue. While some authors 
defend that KTP binding to its specific receptor induces met-encephalin release 
followed by activation of G-protein and Phospholipase C (Ueda, 1987); others report 
that KTP suffers a fast degradation, originating L-Arg, a substrate of nitric oxide (NO) 
synthase. This would induce the formation of NO, leading to the release of met-
encephalin (Arima, 1996; Arima, 1997). Whatever the mechanism, a release of Met-
encephalin is acknowledged by all the authors. 
 
Figure 5 shows possible mechanisms for KTP and L-arginine nociceptive modulation in 
the CNS and periphery. L-Arginine, a semi-essential amino acid, localized 
predominantly in glial cells (Aoki, 1991), is a substrate for enzymes in the central 
nervous system, two of which are nitric oxide synthase (NOS) required for the 
production of nitric oxide (Moncada, 1992) and KTP synthetase, which catalyzes the 
formation of KTP. KTP is also metabolized to L-Arg – a possible substrate for inducible 
and neuronal NOS (Arima, 1996). Some studies revealed that KTP may be able to 
indirectly stimulate the release of endogenous noradrenaline and 5-HT from nerve 
terminals of the descending monoaminergic neurons, mediated by activating the δ-
opioid receptors, resulting in transmission blockade of the nociceptive information in 
the spinal cord (Ochi, 2002). 
KTP-induced nociception is abolished by i.p. injection with NK1 antagonists, by local 
pretreatment with capsaicin to deplete substance P (SP) from nociceptor endings, or in 
mice with targeted disruption of the tachykinin 1 gene. In this way, KTP induced 
nociception through a SP release from SP-containing neurons (Inoue, 1999; Ueda, 
2000). 
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At the same time, it has been found that the action of KTP on integrative brain 
functions in animals, particularly the exploratory activity in an open field, is not 
blocked by naloxone (Dzambazova, 2010). This fact indicates that such types of brain 
activity do not depend on the enkephalin-releasing mechanism of KTP effects. The 
non-analgesic mechanisms of KTP action remain poorly investigated. In addition to 
anti-nociceptive activity, this di-peptide was also reported to have several other 
activities, namely, inhibiting cell proliferation (Bronnikov et al., 1997), anti-hibernating 
regulation (Ignat'ev et al., 1998) and even an epilepsy seizure protection effect 
(Godlevsky et al., 1995). In the peripheral nervous system, KTP has a non-opioid 
activity (Inoue et al., 1997). Sakurada and collaborators, following observation of a 
hypothermic response in mice after i.c.v. injection of KTP, defined that KTP displays a 
thermoregulatory activity (Sakurada et al., 1983). Other authors reported that KTP 
attenuates vasopressin liberation and when in excess mimics the stress response with 
an increase of oxytocin and activation of sympathetic nervous system, with a 
consequent increase of blood pressure (Summy-Long et al., 1998). Regarding 
locomotor behavior, studies with gold fish and i.p. administration in doses starting 
from 200 µg revealed reduction in orientation as result of olfactory and sensorial 
stimuli (Kolaeva et al., 2000). 
 
KTP is unequally distributed in the different brain regions, being more concentrated in 
mid brain, pons and medulla oblongata and spinal cord, which overlap with the brain 
regions more sensitive to morphine microinjection (Ueda et al., 1980). In humans, a 
study using cerebrospinal fluid samples revealed that in patients with persistent pain, 
KTP content is lower, which suggests that kyotorphin acts as a putative neuromediator 
and/or an endogenous pain modulator in the human brain (Nishimura et al., 1991). 
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Points of action 
of inhibitors and 
blockers used: 
(1)L-leucyl-L-
arginine; 
(2) Naltrindole and 
naloxone; 
(3) Naloxone; 
(4) L-nitroarginine 
methyl ester; 
(5) Methylene blue 
 
 
 
 
 
Figure 5 - Possible mechanisms for L-arginine nociceptive modulation in the CNS and periphery, and 
points of action of the inhibitors and blockers employed. KTP, kyotorphin; Met-Enk, methionine-
enkephalin (from Dzambazova, 2010). 
 
 
 
KTP mechanisms of action and the wide range of biological effects make possible the 
assumption that this peptide is a potent neuromodulator and that it can become a 
valuable and marketable drug if modified to have an enhanced BBB-crossing ability, 
while preserving most of its structure and chemistry so that the end result can remain 
effective and nontoxic. Most findings emphasize the effects on the CNS, including the 
spinal cord as well as the brain, but these effects also concern the peripheral body and 
communication across the BBB. Although fifty percent of the total KTP amount is found 
in the cerebral cortex, an area where the contents of opiate receptors and enkephalins 
is low and its physiological effects are opioid and non-opioid mediated, KTP actions are 
far more extensive, hopefully stimulating consideration of possible therapeutic 
applications. 
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4. Peptides as Drugs Candidates 
There has been a rapid expansion in the use of peptides as drugs over the last decade, 
and this is likely to continue. Peptides regulate most physiological processes, acting at 
some sites as endocrine or paracrine signals and at others as neurotransmitters or 
growth factors. They are already being used therapeutically in such diverse areas as 
neurology, endocrinology and hematology. 
Most peptides cannot be administered orally as they are rapidly inactivated by 
gastrointestinal enzymes, so that subcutaneous or intravenous administration is 
required. Therefore, research is focusing on alternative routes of delivery, including 
inhaled, bucal, intranasal and transdermal routes, as well as novel delivery systems 
such as the use of protective liposomes. Neuropeptide systems in the brain are being 
examined as potential targets for therapeutics, providing an exciting future 
development area. The dual problems of local targeted delivery and the blood-brain 
barrier prevent administered peptides from readily gaining access to the required site 
of action. (Edwards, 1999) 
Usually, peptides act by binding to specific cell surface receptors. The perfect 
therapeutic agent would be a small-molecular-mass chemical mimic of the receptor 
ligand, which would be cheap to manufacture and could get to the site of action after 
oral administration. However, receptors are large with many binding sites, and 
peptides have a complex tertiary structure, both of which improve specificity as well as 
affording protection from simple invading molecules, like bacterial toxins. 
Consequently, production of successful peptide mimics using chemical libraries is a 
difficult task and we still largely rely on the native peptide for therapeutics (Edwards, 
1999). 
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Significance and the Increasing Market 
Peptide drugs have been successfully applied in treating certain human diseases. For 
instance, Goserelin (a synthetic gonadotropin-releasing hormone analog) is applied to 
treat breast cancer and prostate cancer. Glatiramer acetate (a synthetic peptide with 
four amino acids) is used for multiple sclerosis and Exenatide (a synthetic glucagon-like 
peptide-1 analog) for type 2 diabetes. The synthetic somatostatin analogs such as 
octreotide and lanreotide are the most common drugs used in treating 
neuroendocrine tumors while conventional chemotherapy and radiotherapy have very 
limited effects. In the commercial market, there is no lack of blockbuster peptide drugs 
generating more than $1 billion in annual sales. However, the annual sales of all the 
approved peptide drugs are only about 20 billion US dollars. This is just a small amount 
(approximately 2%) of the huge drug market. However, the approval rate for peptide 
drugs may be twice as high as that for small molecules. The peptide drug market is also 
growing twice as fast in the worldwide drug market. Currently, there are around 60-70 
approved peptide drugs in the global market, with 100-200 more in clinical trials, 400-
600 more in pre-clinical studies and possibly hundreds to thousands more on the 
laboratory bench (Sun, 2013). In table 3 we can see some of the peptide based drugs 
marketed in the past 10-15 years and the huge investment made. 
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Table 3 – Examples of marketed peptide-based drugs (from Thayer, 2011)
 
 
With the increase of approved peptide-based drugs and the advance in peptide-
associated technologies, peptide-based drug therapeutics will become more significant 
and will open up more commercial opportunities for treating human diseases  
(Castanho, 2011). 
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ARTICLE 1 
Biomedical Applications of di and tri-peptides 
Biopolymers Peptide Science, 2012 
 
I, Sara Matos Santos, declare that the bibliographic research was conducted by me and 
Inês Torcato under guidance of Prof Miguel A.R.B. Castanho. This manuscript was 
written by me under the advice and guidance of my supervisor Prof. Miguel A.R.B. 
Castanho.  
  
49 
 
 
 
50 
 
 
51 
 
 
 
52 
 
 
 
 
53 
 
 
 
 
54 
 
  
55 
 
5. Main Goals of the Project 
This project  aims to unravel the relationship between the mechanisms of pain and 
Alzheimer’s disease (AD). Specifically, we will evaluate the potential of the peptide 
kyotorphin as the link of both diseases. Additionally, 1) its possible use as a marker in 
the diagnosis of Alzheimer´s disease will be addressed and 2) the therapeutic effect of 
recently discovered analgesic kyotorphin derivatives in an animal model of Alzheimer´s 
disease of will be evaluated. With the use of human samples and duly supported by 
studies in animal models, the project will extend the knowledge in the area of new 
pain drugs, diagnosis and treatment of Alzheimer´s disease, aiming at important 
implications for patients suffering from these conditions. 
The main objective of this project is to supplement the gaps of knowledge in a largely 
overlooked area and on which the available information is contradictory:  
1) Relationship between pain and Alzheimer's Disease 
2) Potential for kyotorphin derivatives as analgesic drugs capable of neuromodulation, 
and  
3) Potential of endogenous kyotorphin as a biomarker in Alzheimer´s Disease. 
To achieve these goals we used a multitarget approach: in vivo evaluation of analgesic 
potency, tolerance and side effects of previously synthesized KTP derived peptides, 
pain evaluation of Alzheimer´s disease patients, KTP determination levels in cerebro-
spinal fluid samples of AD patients and testing of KTP effects in an animal model of AD.  
 
In the following sections, published results are presented in the paper format. A brief 
motivation for each study was included. 
Section 2 is dedicated to the theme of pain evaluation in Alzheimer´s disease and 
Section 3 gathers three articles relating to the potential of KTP as an analgesic capable 
of neuromodulation. In section 4, the final conclusions of the thesis are presented. 
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Section 2  
 
Pain in Alzheimer´s 
Disease 
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ARTICLE 2 
The Use of Visual Analog Scales to Compare Pain 
between Patients with Alzheimer’s Disease and 
Patients Without Any Known Neurodegenerative 
Disease and Their Caregivers 
 
American Journal of Alzheimer's Disease and Other Dementias, 2013 
I, Sara Matos Santos, declare that the experimental design, the data collection, the 
data analysis and discussion were carried on by me under supervision of Prof. Miguel 
A.R.B. Castanho. The manuscript was written by me under the guidance of my 
supervisor Prof. Miguel A.R.B. Castanho. 
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Neurologic Diseases and Pain 
Clinical neuroscience studies suggest that chronic pain is dependent on brain function. 
Recent advances in pain research, with the aid of neuroimaging studies, have 
engendered a transformation in our understanding of how pain affects the brain. As a 
result, the notion that changes in sensory systems are the predominant process in 
chronic pain has been replaced by a conceptualization of chronic pain as a very 
complex central nervous system (CNS)  state in which patterns of sensory system 
activation are integrated apparently with activity in other brain systems, including 
emotional, cognitive and modulator processes (Borsook, 2012).  
There are  causes such as peripheral nerve injury-induced pain (neuropathic pain)  that 
affect a large number of brain regions with a wide range of other functions such as the 
anterior cingulate cortex, insular cortex, ventrolateral orbitofrontal area, amygdala, 
striatum, thalamus, hypothalamus, rostral ventromedial medulla, periaqueductal grey, 
pons (locus coeruleus), red nucleus, medulla oblongata and other less obvious causes 
of pain including those associated with primary depression where there is no injury or 
prior pain condition (Borsook, 2012). In many cases, such as in Parkinson´s disease, 
chronic pain is a direct result of the neurological disease, or may even be considered 
an integral part of the underlying disease (Ford, 2010). 
There are both sensory and affective (behavioral) dimensions in pain, and the 
sensation is often accompanied by desires to terminate, reduce, or escape its 
presence. Pain is shaped by the situation in which it emerges, by an individual 
anticipation and emotional feelings. These contextual and cognitive factors are partly 
the result of the fact that pain often occurs in threatening contexts, such as physical 
trauma or disease (Price, 2002). There is a complex interaction between pain effects  
on brain and emotional processing: depression with symptoms such as low energy and 
sleep disturbances, are commonly found in patients with co-morbid pain, whereas the 
opposite is true for symptoms such as guilt and loneliness. Increasingly, major 
depression is seen as being composed of psychological, somatic and painful physical 
symptoms (Lepine and Briley, 2004).  
Part of the affective dimension of pain is the moment-by-moment unpleasantness of 
pain, with feelings such as annoyance, fear, or distress. Pain-unpleasantness is often, 
though not always, closely linked to both the intensity and unique qualities of the 
painful sensation. Another component of pain affect, “secondary pain affect”, includes 
emotional feelings directed toward long-term implications of having pain (e.g., 
“suffering”). These pain dimensions and their interactions relate to ascending spinal 
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pathways and a central network of brain structures that process nociceptive 
information both in series and in parallel (Price, 2002). 
 
Alzheimer’s disease (AD) patients and pain 
Progressive dementia encompasses a variety of diseases, with Alzheimer’s being the 
most prevalent (Cacabelos, 2012). This disease leads to a deterioration of intellectual 
faculties, such as memory, concentration, and judgment, resulting from an organic 
disease or a disorder of the brain. It is sometimes accompanied by emotional 
disturbance and personality changes. Its course is gradual and results in significant 
impairment of social and occupational functioning (Am Psy Ass, 1994). 
Overall, older people are more likely to have painful pathology due to the increased 
incidence of chronic medical conditions, particularly of rheumatologic (osteoporosis, 
osteoarthritis) and oncology fields; pain represents 25-50% of the complaints in 
outpatient and 45-80% of the complaints in institutionalized patients (Scherder, 2008). 
Insufficient use of analgesics for treating nursing home residents with pain was 
frequently reported, especially in those with a low cognitive status (Takai, 2010). 
Several epidemiological studies have shown that in many cases, pain in the elderly is 
not recognized and therefore not treated (Frampton, 2003), which can alter their 
quality of life, increasing phenomena such as depression, aggression, social withdrawal 
and decreased function. 
In the case of AD, studies show that sensory-discriminative components of pain are 
preserved even in advanced stages of the disease (Benedetti, 2004; Schmidt, 2010), 
while pain tolerance increases with disease severity (Benedetti, 1999). However a 
recent study (Jensen-Dahm, 2014) showed no decrease in pain tolerance for mild to 
moderate AD patients. A study by Cole (2006), using brain imaging (fMRI) reports that 
pain perception and processing are not diminished in AD. 
The motor and cognitive impairment in AD patients is accompanied by a reduction in 
the ability to communicate, which makes it difficult to detect pain in these patients. By 
failing to obtain adequate pain treatment, structural and irreversible changes may 
occur in central systems structures involved in the transmission/modulation of 
nociceptive information, which accounts to chronic pain installation (Borsook, 2012). 
Curiously, the two components of the pain response are differentially affected in AD 
patients (Benedetti, 1999; Farrell, 1996): whereas the sensory-discriminative 
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component is preserved, pain tolerance, associated with the affective-emotional 
aspect, largely increases. 
These apparent discrepancies appear to have a neurobiological explanation since the 
somatosensory cortex and thalamic nuclei involved in sensory-discriminating 
component of pain response appear to be preserved in AD, while the neuronal loss 
was detected in the prefrontal and limbic structures, with obvious implications for 
affective-emotional pain-related reactions (Scherder, 2008). 
Alzheimer’s disease is a double-edged sword when it comes to pain assessment. Pain 
affects cognitive function (Moriarty, 2011) and cognitive function also affects pain 
assessment and pain treatment because the primary method for pain assessment is 
still patient reporting (Licht, 2009). 
The evaluation of pain, with no specific test or tracers and large individual variability, is 
always complex. To worsen matters, in the case of dementias one third of the patients 
are in later stages of the disease, therefore unable to complete a proper evaluation 
(Krulewitch, 2000). According to the 2002 “American Geriatrics Society Panel on 
persistent pain in older persons”, the assessment of pain is extremely important in 
patients suffering dementia and should be performed using validated scales. There is 
evidence that the administration of pain questionnaires can be reliable in mild and 
moderate cognitively impaired people (Rastogi, 2012), although there are fears about 
the expressive and receptive language abilities, which deteriorate during the course of 
AD (Martine, 1983). As children under 7 years old also have problems with language, 
use of visual analogue scales (VAS) developed for them can be reliably administered in 
early/moderate patients with AD (Martine, 1983; Scherder, 2000). A variety of 
instruments are available to measure pain intensity. Psychometric evaluation of pain 
intensity scales suggests that variations of the numeric rating scales (NRS), verbal 
descriptor scale (VDS), faces pain scales (FPS), and visual analogue scale (VAS) are 
appropriate for use with older adults. As mentioned earlier, a prerequisite for selecting 
an appropriate pain measurement scale involves determining the individual’s ability to 
learn, and understand the directions for completing the tool (Herr, 2001). 
Many times, the health professional evaluating patients with AD relies on the family 
caregiver testimony, which accuracy may be impacted by behavioral changes of the 
patient and be in potential disagreement with that of the patients themselves (Karp, 
2008; Miaskowski, 1997; Arons, 2013). In the case of AD, studies comparing self-report 
and family caregiver pain perception are scarce. However, many actuation protocols in 
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the field of pain are based on caregiver report. Moreover, accurate pain and comfort 
assessment relieves patient and caregiver associated stress (Lim, 2004). 
 
Outline and main findings of the experimental work 
The objectives of this study were 1) to compare the pain intensity and to a lesser 
degree pain affect both in AD and in cognitively normal patients and 2) to analyze the 
difference in pain perception between patients and their family caregivers. We 
evaluated the pain intensity report of 121 patients with chronic osteoarticular pain, 60 
with mild to moderate AD and 61 without any know neurodegenerative disease, using 
the colored pain scale/faces pain scale (CAS/FPS), and the caregiver’s perception.  
Self-report is a valuable tool to assess pain intensity because it is simple to use in the 
daily setting and permits to evaluate the variation of pain in the same individual during 
time (Herr, 2001). It was also shown that elders without cognitive impairment and 
those in early stages of disease can report their pain degree in a reliable way (Pautex, 
2006). However, studies also point to AD patients reporting less pain as their disease 
progresses (Scherder, 2008; Farrell, 1996; Herr, 2001). 
In our study, both in the case of CAS and FPS, AD patients reported significantly less 
pain in comparison with normal (N) patients. Furthermore, the discrepancy between 
FPS and CAS was higher in AD than in N group. These results suggest that even in mild 
to moderate cases of the disease, pain perception can be affected, with demented 
patients reporting less pain. Also, the discrepancy between FPS and CAS could also 
suggest that the affective component of pain in AD is compromised relatively to 
normal patients, and/or that AD patients do not value their complaints even in 
mild/moderate stages of the disease. 
We also found that, in contrast to other caregiver pain reports, namely in the oncology 
field (Yeager, 1995; Arons, 2013), family caregiver considered the pain degree of their 
relative substantially lower in the case of AD patients. This is important since in most 
cases surrogates are the primary source of information regarding the well-being of AD 
patients, and health professionals rely on the caregiver information to add or alter 
prescribed drugs such as painkillers.  
As mentioned earlier, most researchers agree that in patients with dementia, 
particularly of the Alzheimer type, sensitivity to pain is kept, although the emotional 
component, dependent on higher brain structures is reduced or even abolished. This 
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means that AD patients present less pain complaints which appear to decrease as the 
disease progresses. Our study supports this: we found that in patients with prior 
osteoarticular pathology, with and without Alzheimer’s, AD group reported less 
subjective pain, and that their pain was not as perceived by their family caregiver as in 
normal patients. 
This study also points to the need of, when evaluating AD patients, always measure 
their pain level using appropriate scales instead of solely depending on the information 
provided by their primary care provider. 
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Kyotorphin and 
derivatives in 
Alzheimer´s Disease 
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ARTICLE 3 
Neuropeptide kyotorphin (tyrosyl-arginine) has 
decreased levels in the cerebro-spinal ﬂuid of 
Alzheimer’s disease patients: potential diagnostic 
and pharmacological implications 
 
Frontiers in Aging Neuroscience, 2013 
 
I, Sara Matos Santos, declare that the experimental design, the sample collection and 
the data analysis and discussion were carried out by me under supervision of Prof. 
Miguel A.R.B. Castanho. The manuscript was written by me under the guidance of my 
supervisor Prof. Miguel A.R.B. Castanho. Laura Garcia-Nimo and Prof. José Cocho 
developed the mass spectrometry techniques capable of quantifying KTP in CSF. Sónia 
Sá Santos and Prof. Isaura Tavares collaborated in the results, discussion and 
preparation of the manuscript.  
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Kyotorphin as a possible biomarker in Alzheimer´s Disease 
 
As shown in previous studies – see introduction and article 2 - underestimation of pain 
is frequent in Alzheimer´s disease, which leads to two undesired clinical settings: 1) 
Unrelieved suffering of the patients due to inadequate treatment, and 2) Pain itself is a 
factor that contributes to the aggravation of neurodegeneration. The benefits of 
finding a biomolecular marker for pain is two-fold: i) To have an objective material 
parameter to estimate pain, regardless of the state of the cognitive impairment of the 
patient, and ii) The biomarker molecule itself may be involved in the mechanism of 
pain/nociception and therefore constitute a drug lead worth developing. The quest for 
a biomarker of pain, which would additionally be able to potentially be used as anti-
nociceptive drug, is an endeavor worth pursuing. Our work is a contribution towards 
this end. 
Despite KTP efficient analgesic activity, which is about 4 times higher than the 
endogenous opioids (Shimoni, 1981), it has been suggested that KTP has 
neuromodulating and neuroprotective (in hippocampus and cerebellum) properties 
(Bocheva, 2004; Nazarenko, 1999), as well as an antiepileptic effect (Ribeiro, 2011). 
This data led us to the hypothesis that KTP-NH2 may be simultaneously an analgesic 
and neuroprotective drug by interfering with cellular pathways that are common to AD 
progression and analgesia. It was shown by others that KTP, due to its L-arginine 
group, could act as substrate for nNOS (nitric oxide synthase located in neurons) 
(Arima, 1997). Indirectly, this NO release causes opioid-like actions, producing 
analgesia through the release of met-enkephalin (Bocheva, 2004). Moreover, in recent 
years, there has been accumulating evidence that AD may be primarily a vascular 
disease with neurodegenerative consequences (de la Torre, 2004). The convergence of 
two key factors (i.e. aging and decreased cerebral perfusion) for AD to develop, results 
in a critically attained threshold of cerebral hypoperfusion (CATCH), which promotes 
distortion of brain capillary structure and impairment of NO homeostasis. Tissues that 
do not maintain the basal level of NO are more predisposed to an amendment of their 
regulation, extending the excitatory state. Thus, the advanced ageing associated with a 
vascular risk factor may contribute to endotheliopathies involving basal NO deficit to 
such a degree that it could initiate the neurodegenerative changes of AD (de la Torre, 
2000). Brain cell death may in turn cause a decreased level of endogenous KTP in the 
brain, which further impacts on chronic pain. 
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Outline and main findings of the experimental work 
The above mentioned data led us to the hypothesis that kyotorphin is a key-molecule 
linking molecular mechanisms of pain and neurodegeneration. More specifically, we 
were prompted to test the hypothesis that decreased levels of kyotorphin in AD 
patients would contribute to chronic pain in these patients. Should this hypothesis 
proven true, the resulting chronic pain is a contribution to neurodegeneration and a 
detrimental cycle is created: pain worsens AD and AD worsens pain.  
Kyotorphin levels in the cerebro-spinal fluid (CSF) of AD patients were correlated to 
phosphorilated protein Tau levels, which is a validated biomarker for AD (Prvulovic, 
2011). Levels of total Tau/phosphorylated Tau (p-Tau181P) reflect tangle formation. 
The origin, structure, and function of these proteins are shown in Figure 6 for Tau 
isoforms. Well established ELISA-based testing methods are available for assessment 
of candidate CSF biomarkers such as CSF p-Tau181P or p-Tau231P. In contrast, the 
detection and quantification of kyotorphin levels in CSF is very far from being trivial. 
Detecting nanomolar or sub nanomolar analytes in a biological matrix such as CSF is a 
demanding analytical and instrumental challenge. This serious limitation made us 
team-up with collaborators in the laboratory of metabolopathies of the Clinical 
Hospital of Santiago Compostela, Spain, whom are specialists in the application of 
Mass Spectrometry to detect biomarkers in biological fluids. It was necessary to resort 
to advanced analytical techniques, namely electrospray ionization tandem mass 
spectrometry (ESI–MS/MS). Calibration solutions were prepared with different 
additions of KTP in a CSF matrix, were at concentrations from 0.625 to 10nM. We 
obtained a detection limit of 0.8nM. We used an API4000 triple quadrupole mass 
spectrometry (SciexAppliedBiosystems) equipped with an electrospray source with the 
turbo gas temperature set at 750°C. The equipment was operated in positive ionization 
polarity at a potential of 5400V. After fine tuning the sophisticated instrumental setup 
and the methodologies, the difficulties were overcome and we succeeded in 
determining with high precision in the CSF the levels of kyotorphin, which were later 
correlated to p-Tau levels in CSF. 
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Figure 6 - The tau protein. The domain structure of the tau isoforms (tau gene location: 17q21) that are 
expressed in the human brain are shown. The isoforms differ (1) in the number of tubulin-binding 
domains (three or four repeats located in the C-terminal half of the protein; referred to as 3R or 4R tau 
isoforms) and (2) in the presence or absence of either one or two 29-amino-acid-long, highly acidic 
inserts at the N-terminal portion of the protein (the projection domain). The flow towards neurotoxicity 
is shown. (MT = microtubule; NFT = neurofibrillary tangles; PHF = paired helical filaments). 
(Vanderstichele, 2008) 
 
Having gathered CSF samples of twenty five AD patients in different stages of the 
disease (i.e. a wide range of p-Tau levels), we found decreasing levels of kyotorphin 
with AD progression. The negative correlation between KTP levels and p-Tau is clear 
(Figure 2 in the paper). The hypothesis of KTP being a molecular link between pain and 
neurodegeneration is thus valid and new avenues are open in clinical research in the 
largely unexplored domain of pain in patients with cognitive impairment. It is equally 
important to pursue the stimulating hypothesis that KTP derivatives of 
pharmacological interest to fight pain may also have in itself a neuroprotective effect, 
unifying in a single strategy the amelioration of pain and neurodegeneration. 
 
 
Compromised Axonal Transport 
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Supplementary Material to Section 3 (Article 3) 
 
 
Figure S1. Calibration curve of KTP (kyotorphin) in a CSF matrix (0.625–10 nM). 
Figure S2. Multiple reaction monitoring (MRM) measurements, with Q1 394.3 and Q3 136.1, 
using an API 4000 triple quadrupole mass spectrometry (Sciex Applied Biosystems) equipped 
with an electrospray source. 
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ARTICLE 4 
Amidated and ibuprofen-conjugated kyotorphins 
are neuroprotective in the hippocampus and 
improve spatial working memory after bilateral 
carotid occlusion in female rats 
In preparation for submission 
 
 
 
I, Sara Matos Santos, declare that the experimental design, the animal experimentation, data 
collection, data analysis, and conclusions were carried by me under supervision of Prof. Miguel 
Castanho and with the collaboration of Sónia Sá Santos. 
Antónia R.T. Pinto helped in animal experimentation. 
Synthesis of Kyotorphin and Ibuprofen-Kyotorphin were performed by Prof Montesserat Heras 
and Prof. Eduard Bardají. 
A manuscript for publication will be prepared by Prof Isaura Tavares, Prof Miguel Castanho, 
Sónia Sá Santos and I.  
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Outline and main findings of the experimental work 
 
Following the work presented in previous chapters, it was imperative to evaluate the 
efficacy of kyotorphin derived peptides in an animal model of AD. In recent years, 
investigators have increasingly tended to accept that AD may be primarily a vascular 
disease with neurodegenerative consequences (de la Torre, 2000), rather than a 
neurodegenerative disorder with vascular consequences, and that ischemic states 
associated with aging like carotid insufficiency can lead to a chronic disruption of 
cerebral blood flow, which induce neurological deficits and dementia, such as AD 
(Bennet, 1998). 
With that premise in mind and duly supported by previous work from other groups 
(Farkas, 2007), we conducted bilateral carotid occlusion in a group of rats in order to 
mimic the neurodegeneration observed in humans due to shortage of cerebral blood 
flow. This model is particularly interesting because there is neuronal death in key 
memory areas such as the hippocampus (Farkas, 2007). 
In this study, KTP-NH2 and IbuprofenKTP-NH2, which had already shown pronounced 
analgesic activity after systemic administration, were neuroprotective in the 
hippocampus and improved spatial working memory in the rat model of 
neurodegeneration. This finding is encouraging and opens the window to new studies 
to evaluate if these peptides can be a weapon to fight conditions such as AD. 
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Amidated and ibuprofen-conjugated kyotorphins are 
neuroprotective in the hippocampus and improve spatial 
working memory after bilateral carotid occlusion in female rats 
 
 
 
 
 
 
Abbreviations used:  
2VO, two-vessel occlusion; AD, Alzheimer’s disease; BBB, Blood-Brain Barrier; CATCH, critically 
attained threshold of cerebral hypoperfusion; CNS, Central Nervous System; CSF, cerebrospinal 
fluid; DMSO, Dimethyl sulfoxide; GFAP, glial fibrillary acidic protein; H&E, hematoxylin and 
eosin; i.p., intraperitoneal; KTP, kyotorphin; KTP-NH2, kyotorphin-amide; IbKTP-NH2, KTP-NH2 
linked to Ibuprofen; NFL, neurofilament-L protein; OFT, open field test; PBS, phosphate 
buffered saline; SEM, standard error of the mean. 
 
Running Title: Neuro-modulating effects of KTP derivatives   
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ABSTRACT  
Chronic brain ischemia is a prominent risk factor for neurological dysfunction and progression 
for dementias, including Alzheimer’s disease (AD). In recent years, there has been 
accumulating evidence that AD may be primarily a vascular disease with neurodegenerative 
consequences, rather than a neurodegenerative disorder with vascular consequences. 
In rats, permanent bilateral ligation of the common carotid arteries (two-vessel occlusion, 
2VO) causes progressive and irreversible cognitive impairment with Alzheimer’s phenotype: 
learning difficulties and memory loss, failure of neuronal signaling, neuropathological damage 
in the hippocampus and cerebral cortex within a variable time frame since occlusion. 
Kyotorphin (KTP) is an endogenous dipeptide (L-Tyr-L-Arg) that plays an important role in pain 
regulation at the central nervous system (CNS). It has also been suggested that KTP has 
neuromodulating and neuroprotective properties. We have recently succeeded in designing 
two new KTP derivatives, KTP–amide (KTP–NH2) and KTP–NH2 linked to ibuprofen (IbKTP–NH2), 
with antinociceptive action following systemic administration. 
The objective of our work was to investigate the effects of KTP–NH2 and IbKTP–NH2 on motor 
function and spatial recognition memory and histopathological alterations at the hippocampus 
of female rats in chronic cerebral hypoperfusion (2VO-rat model).  
Overall, our experimental findings show that KTP-derivatives, mainly IbKTP-NH2, improved 
cognitive impairment and and prevented neuronal damage in hippocampal CA1 subfield, 
induced by chronic cerebral hypoperfusion.  This means that these compounds, besides its 
already known analgesic efficacy, are also capable of acting in key brain areas as positive 
neuromodulators or slowing neurodegeneration, being potentially useful in the treatment of 
dementia.  
 
 
Keywords: kyotorphin derivatives, analgesic drugs, chronic cerebral hypoperfusion, 2VO rat 
model, cognitive impairment, locomotor function, dementia   
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INTRODUCTION  
Current estimates indicate that 35.6 million people worldwide are living with dementia, a 
number that is expected to nearly double every 20 years [1]. Chronic brain ischemia is a 
prominent risk factor for neurological dysfunction and progression for dementia  including 
Alzheimer’s disease (AD) [2-4]. In fact, AD is the most prevalent neurodegenerative disease in 
the elderly, responsible for about 50-70% of cases of dementia [5]. This irreversible disease is 
characterized by progressive deterioration of cognitive and memory functions, formation of 
amyloid plaques and neurofibrillary tangles as well as profound alteration in glial responses, 
cholinergic dysfunction, extensive synaptic and neuronal loss [6-8]. Moreover, in recent years, 
there has been accumulating evidence that AD may be primarily a vascular disease with 
neurodegenerative consequences, rather than a neurodegenerative disorder with vascular 
consequences [7]. The convergence of two key factors (aging and decreased cerebral 
perfusion) for AD to develop, results in a “critically attained threshold of cerebral 
hypoperfusion” (CATCH), which promotes distortion of brain capillary structure and 
impairment of nitric oxide (NO) release [9]. 
Experimental animal models have been improved to investigate circulation-dependent 
behavioral deficits resultant of chronic cerebrovascular insufficiency as it occurs in human 
aging and AD [3]. In rats, permanent bilateral ligation of the common carotid arteries (two-
vessel occlusion, 2VO) causes progressive and irreversible cognitive impairment with 
Alzheimer’s phenotype: learning difficulties and memory loss, failure of neuronal signaling, 
neuropathological damage in the hippocampus and cerebral cortex within a variable time 
frame since occlusion [3]. In the 2VO-model there is neurodegeneration of various cerebral 
structures, particularly in the CA1 pyramidal cell layer of the hippocampus, a brain region 
known to be highly implicated in spatial learning and memory [10], and also susceptible to 
postischemic inflammatory phenomena and β-amyloid peptide accumulation [11,12].  
Kyotorphin (KTP) is an endogenous dipeptide (L-Tyr-L-Arg) that plays an important role in pain 
regulation at the central nervous system (CNS) [13-15]. It was first isolated from bovine brain 
by Takagi and colleagues in 1979 [14, 15], and subsequently found in the brains of other 
mammals, including in human cerebrospinal fluid (CSF) [16]. The remarkable analgesic activity 
of KTP in animal models was observed only when the molecule was directly injected into the 
brain [17], which is a consequence of its reduced ability to cross the blood–brain barrier (BBB). 
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To improve KTP delivery to CNS, we have recently succeeded in designing two new KTP-
derivatives: KTP–amide (KTP–NH2) and KTP–NH2 linked to ibuprofen (IbKTP–NH2) [18, 19] 
(Figure 1). Both derivatives proved to induce strong analgesic activity following systemic 
administration to model animals [18, 19], with the absence of the major side-effects when 
compared to clinically relevant opioids [20].  
In addition to analgesic activity, it has been suggested that KTP has neuromodulating and 
neuroprotective (in hippocampus and cerebellum) properties [21, 22], as well as an 
antiepileptic effect [23].  
KTP is synthesized in nerve terminals and released by depolarizing stimuli [24]. It may 
modulate the synaptic transmission and directly excite cortical neurons. It was proposed that 
KTP, due to its L-arginine group, could act as substrate for nNOS (nitric oxide synthase located 
in neurons), with subsequently formation of NO which would then induce analgesia via met-
encephalin release [25]. Moreover, it has been proposed that disruption of NO homeostasis 
may hasten the development of AD. In fact, the prolonged brain hypoperfusion brought on by 
CATCH seems to promote regional endotheliopathies due to basal deficit of NO that over time, 
can evolve to such a degree that lead to AD symptoms and to progressive neurodegeneration 
[9]. Additionally, when neuronal death occurs it may in turn cause a decreased level of 
endogenous KTP in brain which further impacts on chronic pain and impairment of NO 
production.  
Our recent clinical studies support there is a link between AD, pain and KTP in humans. In fact, 
not only we observe that pain is underestimated in AD patients [26] but also that  KTP has 
decreased levels in the CSF of AD patients [27]. Moreover, there was an inverse correlation 
between levels of phosphorylated-tau protein (a molecular marker of AD progression) and of 
KTP [27]. 
In brief, the analgesic KTP and its derivatives have shown important properties that may 
influence de course of AD: neuromodulation and neuroprotection, substrate for nNOS, role as 
a neuroleptic agent inhibiting calcium-dependent currents in the postsynaptic membrane.  
The present study was conducted to investigate the effects of chronic treatment with KTP-
derivatives (KTP-NH2 and IbKTP-NH2) on memory impairment, motor function, and 
hippocampal injury in a 2VO rat model. 
 
93 
 
MATERIALS AND METHODS  
Ethics Statement 
All described procedures were conducted in compliance with the European Community 
legislation (Directive 2010/63/EU), and were approved by the Ethical Committee for Animal 
Research of the Faculty of Medicine, University of Lisbon, and the Portuguese Competent 
Authority for Animal Welfare (DGV). 
 
Compounds 
The peptides KTP–NH2 and IbKTP–NH2 were synthesized as described elsewhere [18, 19] 
Anesthetic and analgesic drugs used during and post-operative procedure: Imalgene® 1000 
(Ketamine 100 mg/mL; Merial, France); Domitor® (Medetomidine hydrochloride 1 mg/mL; 
Pfizer, Orion Pharma, Finland); Antisedan® (Atipamezole hydrochloride 5 mg/mL;  Pfizer, Orion 
Pharma, Finland); Budale® (Buprenodale 0.3mg/mL; Dechra, UK). 
 
Animals and housing 
Young female Sprague-Dawley rats weighing 225-250 g (3 months of age) were purchased to 
Charles River Laboratories (Barcelona, Spain). They were housed together in groups of 3-4 per 
cage with unrestricted access to water and food, and under controlled temperature and light 
conditions (22 ± 2ºC; lights on between 7 a.m. and 7 p.m.). Surgical procedures and all 
behavioral experiments were conducted during the light period of the 12:12 h cycle. 
 
Surgery: two-vessel Carotid artery occlusion procedure 
One week after animal’s arrival to the Rodent Facility, permanent global ischemia and sham 
surgery was performed as described elsewhere [28,29]. Briefly, animals were anaesthetized for 
surgery with a mixture of ketamine (75 mg/kg BW, i.p.) plus medetomidine (4 mg/kg BW, i.p.). 
A neck ventral midline incision was made and both common carotid arteries were exposed and 
carefully separated from carotid sheath, cervical sympathetic and vagus nerve. For occlusion, 
each carotid artery was double-ligated with 5-0 silk sutures just below the carotid bifurcation. 
Sham-operated animals were subjected to the same surgical procedures without carotid artery 
ligation. 
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During the surgery, the animals were breathing spontaneously and body temperature 
maintained around 37°C by a self-regulating heating pad. After the procedure, rats were i.p. 
injected with the medetomidine reversing agent mixture (Antisedan®, dose of 1 mg/kg BW) 
and kept on heating pad until they recovered from the anesthesia. Afterwards, all animals 
were returned to their home cages with free access to food and water. During the first 24h 
post-surgery, Budale® was administrated for pain relief purposes (dose volume of 0.05mL/150-
300g BW q 8-12h). Animals were closely monitored during the post-operative recovery for 
appearance, activity, feeding behavior and body weight. Like in larger surgical interventions, 
2VO is typically followed by an initial decrease in body weight [3] but all animals involved in 
this study regained their weight before behavioral testing. Body weight was measured before 
the surgery and controlled whenever the animals were handled for i.p. injection and/or 
experimentation. 
 
Rat treatment regimen 
KTP–NH2 and IbKTP–NH2 were dissolved in physiological saline solution (0.9 % NaCl containing 
5 % of dimethyl sulfoxide, DMSO) prior to intraperitoneal (i.p.) injection (in a dosing volume of 
1 mL/kg BW). KTP-derivatives were administrated as a chronic treatment regimen during 7 
consecutive days (single i.p. dose/day) in two different timings: (A) one week and (B) four 
weeks after the onset of 2VO surgery.  
Experimental groups were as follows: (1) sham-operated group; (2) 2VO control group; (3) 2VO 
animals receiving KTP–NH2 i.p. (32.3 mg/kg = 96 µmol/kg); and (4) 2VO animals receiving 
IbKTP-NH2 i.p. (24.2 mg/kg = 46 µmol/kg). The selected doses of KTP-derivatives were based on 
our previous results concerning their analgesic action profile [18-20]. Moreover, the control 
2VO- and sham-operated groups were i.p. injected with the vehicle solution. A time line of 
experimental events is depicted in Figure 2. 
 
Behavioral test procedures 
All behavioral studies were carried out between 9 a.m. and 6 p.m. in animals accustomed to 
the testing room and to researchers performing the trials. During the fifth week post-2VO 
surgery (Fig. 2), rats were tested in standard behavioral paradigms to examine spontaneous 
locomotor activity (open-field test) and spatial recognition memory (Y-maze). All behavioral 
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apparatus were thoroughly cleaned after each rat to mitigate olfactory stimuli. At the day of 
experiments, animals were brought into the testing room for at least 2 h prior to the start of 
the behavioral session. 
 
Motor function testing: Open field 
Open field test (OFT) is a widely used test of locomotion activity, exploratory and anxiety 
behaviors [30]. The open field apparatus consisted of an empty square box (67 x 67 x 51 cm 
height), “virtually” divided in three concentric squares: borders (near the walls), periphery and 
center. Without prior habituation, locomotor behavior was measured in a quiet room with 
dimmed light. Testing protocol has been described in detail previously [20]. Briefly, fifteen 
minutes after i.p. injection (with one of KTP derivatives or with the vehicle) rats were placed 
individually in the center of the arena box and allowed to explore the apparatus for 5 min. 
Their behavior was video-recorded during the testing period. Animal tracking along the 
different areas on the open field arena was analyzed using specific software (Smart version 
2.5.10 program; Panlab, S.L.U, Barcelona, Spain). The experimenter was out of sight from the 
rat during the OFT. To evaluate the number of crossings, the open field arena was also virtually 
divided into 16 equal rectangles, and the number of times each animal crossed between two 
areas was measured. Results are shown as average velocity, % of time resting, number of 
crossings and % of time spent in the center of arena.  Each animal was considered to be resting 
if the mean velocity was < 3 cm/s. Average velocity is the mean velocity with the resting time 
excluded. All animals were tested only once. 
 
Memory testing: Y-Maze 
Y-maze is a simple two-trial recognition test for measuring spatial memory skills [31]. The 
experimental protocol was similar as the one described in [32]. Briefly, Y-shaped apparatus 
comprises three identical arms at a 120° angle from each other (arm dimensions, 35cm long x 
10cm wide x 20cm high). Those three arms were designated as “Start arm”, in which the rat 
starts to explore (always open), “Novel arm”, which is blocked at the 1st trial, but open at the 
2nd trial, and “Other arm” (always open). Animal bedding was used to cover the floor of the 
maze and was mixed after each individual trial to prevent rats from using odor cues in maze 
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navigation. The experimenter was never present in the room while the animals explored the 
maze. Two separated trials were performed: the first one had 10 min duration and allowed the 
animal to explore freely only two arms (Start and Other) since the third arm (Novel) was 
blocked with black Plexiglas. Then, after an interval of 1 h, the rat was placed in same starting 
arm, with free access to all three arms for 5 min (2nd trial). Animal behavior was video-
monitored, enabling the number of total entries (sum of entries in all three arms, i.e. 
Novel+Other+Start arms) and time spent in Novel and Other arms to be analyzed. Entry was 
considered to be complete when all four limbs were within an arm. No animal had jumped out 
of the maze arena during the testing period. 
 
Histopathology and Immunofluorescence 
After the last behavioral test, rats were anesthetized using ketamine/medetomidine mixture 
and perfused transcardially with 0.9% saline solution, followed by 4% paraformaldehyde in 
phosphate buffer (pH 7.4). Following decapitation, their brains were carefully removed, 
maintained for post-fixation in the same fixative solution at 4°C for 24 h and then 
cryoprotected with a 30% sucrose solution for at least two days.  
Brains were gelatin-embedded and then sectioned at a thickness of 15 µm on a cryostat (LEICA 
CM 3050S, Nussloch, Germany). Only the coronal sections located at the level of dorsal 
hippocampus (around - 3.6 mm posterior from bregma [33]) were collected, mounted on 
SuperFrost® Plus slides (Menzel-Glaser, Braunschweig, Germany) and further processed for 
Hematoxylin-Eosin (H&E) staining and immunofluorescence. 
H&E staining was performed in the first set of sections, in order to detect the location of areas 
of ischemic brain damage, as well as to examine changes in laminar structures of the 
hippocampus namely pyramidal cell layers in the cornu ammonis (i.e., CA1, CA2 and CA3) 
subfields. The H&E-stained sections were observed under a brightfield microscope (Leica 
DM2500, 12.5x and 50x magnifications). 
For the immunofluorescence studies, the second set of hippocampal sections was double-
stained for the astrocytic marker mouse anti-glial fibrillary acidic protein (GFAP, 1:200; catalog 
#MAB3402, Milipore) and for the neuronal marker rabbit anti-neurofilament-L protein (NFL, 
1:50; catalog #AB9568, Milipore). Briefly, slides were placed in PBS for 10 min at 37oC to 
remove gelatin from brain tissue. Sections were subsequently treated with 0.1% Triton X-100 
97 
 
in PBS (PBS-Tx) for membrane permeabilization, blocked for 1 h with 2 % bovine serum 
albumin (BSA) in PBS at room temperature (RT), and then incubated at 4 ◦C overnight with the 
mixture of primary antibodies prepared in blocking solution (2% BSA in PBS). In the following 
day, sections were washed in PBS-Tx and incubated with the secondary antibodies goat anti-
mouse IgG Alexa 488 (1:200; catalog #A11017, Molecular Probes) and goat anti-rabbit IgG 
Alexa 594 (1:200; catalog #A11012, Molecular Probes) for 1 h at RT in a humified dark 
chamber. For nuclei staining, sections were incubated with Hoechst 33342 (Life Technologies) 
for 10 min at RT protected from light. At the end, sections were cover slipped with ProLong® 
Gold antifade reagent (Life Technologies). Negative controls in which the primary antibodies 
were omitted were performed simultaneously.  
All samples were analyzed on a confocal point-scanning microscope (Zeiss LSM 510 META) 
using excitation wavelengths of 405, 488 and 594 nm. Immunofluorescence images were 
capture (400× magnification) in two randomized areas of dorsal CA1 subfield in both 
hemispheres, i.e. CA1 images were taken bilaterally in each rat.  All acquisition conditions were 
kept constant between samples during the capture process.  
Tissue background was determined and since its autofluorescence was negligible, background 
subtraction was not required for imunofluorescence quantification. Image J 1.48C Software 
was used to measure the intensities of the fluorescence signals for GFAP and NFL, after gray-
scale threshold determination. One measurement was taken from each hippocampus of each 
animal (2 measurements per rat, 3 to 4 rats per group) rendering a total of 6 to 8 data points 
per group. 
 
Statistical analysis  
Data are represented as the groups’ mean ± SEM (standard error of the mean).  
All statistical analyses were calculated with Prism Software (GraphPad Software, version 6, La 
Jolla, CA, USA). The significance of differences between groups was analyzed with one way 
ANOVA followed by Tukey’s or Bonferroni´s multiple comparison test when indicated. 
Differences in immunofluorescence measurements between two groups were analysed with 
Student's t-test (unpaired). Statistical significance was defined as p<0.05.  
 
  
98 
 
RESULTS 
Histopathological and immunofluorescence evaluation 
Representative photomicrographs of hippocampal sections stained with H&E are shown in 
Figure 3. In some animals subjected to 2VO surgery, brain tissue loss was observed (Fig. 3 A): 
ischemic regions were colored white, while the non-ischemic regions were colored pink.  
As can be seen in Figure 3 B, 2VO-control animals showed significant unilateral changes (right 
or left hemisphere) in the histoarchitecture of the cornu ammonis (i.e., CA1, CA2 and CA3) 
subfields reflected by the loss of pyramidal cells layers. These degenerative changes were not 
observed in the two KTP-treated 2VO groups (i.e., KTP-NH2 and IbKTP-NH2). 
In order to evaluate the effects of KTP derivatives on astrocytic responses and against neuronal 
damage in CA1 subfield, immunofluorescence studies were performed. One of the major 
components of the axonal cytoskeleton, the neurofilament-L protein (NFL) was used as 
neuronal marker. Glial fibrillary acidic protein (GFAP) was used as astrocytic marker.  
Representative images of hippocampal CA1 region double-stained for GFAP and NFL are 
presented in Figure 4. As can be seen, the NFL signal intensity for the 2VO-control group was 
particularly lower when compared with the sham - control group and both KTP-treated 2VO 
groups. Apparently, no major changes in GFAP signal were detected between all animal 
groups. 
To confirm this qualitative analysis, the fluorescence signals for GFAP and NFL were quantified 
(Table 1). In fact, no significant effects on GFAP immunofluorescence were observed in the 
three 2VO-groups when compared to the sham-control group. As expected, there was a 
significant decrease in NFL content in 2VO-control group (P=0.0004 vs. sham group; P< 0.0001 
vs. KTP-NH2 group; P=0.009 vs. IbKTP-NH2 group). In contrast, the NFL immunofluorescence 
results for KTP-NH2 and IbKTP-NH2 groups were similar to those in the sham - control group. 
 
Open Field test 
Locomotor activity in a new environment was measured in an open field apparatus. A 5 min 
session was chosen as this time period is known to emphasize rodent exploratory behavior and 
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response to novelty [30] as well as to detect anxiety-like tendencies, significant hyperactivity 
or behavioral sedation [30].  
As shown in Figure 5, there were no differences between the vehicle-treated animals (i.e., 
sham-operated and 2VO controls) for the velocity parameter, % of time resting and number 
crossings. In fact, the only significant difference between the sham-operated rats and the 
three 2VO-groups was the % of time spent in the center of the arena (Fig. 5 C), i.e., all the 2VO-
animals exhibit a more pronounced anxious behavior. 
Moreover, the pattern of locomotor response is clearly different in IbKTP-NH2-treated 2VO 
group as those animals moved slower (Fig.5 B, p < 0.01 vs. both controls), spent more time 
resting (Fig.5 A, p < 0.001 vs. both controls) and crossed less frequently between areas (Fig.5 
D, p < 0.001 vs. both controls). These results show that the locomotor performance was 
affected to a certain extent. No significant effects of KTP-NH2 are detected relative to 2VO- 
controls.   
 
Y Maze 
Figure 6 shows the results for the performance of KTP-treated 2VO animals in Y-maze task, in 
which short-term spatial recognition memory was evaluated. 
To determine if the motivation to explore the maze apparatus was the same among the groups 
during the testing period, the number of total arm entries was analyzed. There was no 
difference found between all animal groups in terms of total number of arm entries (Fig.6 A). 
Analysis of which arm was chosen to be explored first revealed similar outcomes between 
sham-operated and IbKTP-NH2-treated groups: i.e., all those animals entered the Novel arm as 
the first choice (100%), whereas the 2VO-control group chose unanimously the Other arm to 
go first. The percentage of animals that entered Novel arm as first choice in KTP-NH2 group 
was 60%. 
As can be seen in Figure 6, there was no difference between the sham-operated group and the 
KTP-treated 2VO groups for the % of time spent in the Other arm and in the Novel arm (Fig.6 
C). On the other hand, the 2VO-control group spent less time in the Novel arm when compared 
with sham-operated animals. Moreover, the analysis within each experimental group showed 
that the ischemic 2VO-control group explored the Other arm significantly more than Novel arm 
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(p < 0.0028, Fig.6 C), whereas all the other groups (sham and KTP-treated 2VO animals) spent 
similar amount of time both in the Novel and Other arms (Fig.6 C). 
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DISCUSSION 
It is now consensual that ischemic episodes of brain, which is critically dependent of a 
continuous blood supply to maintain its activity, trigger a cascade of degenerative events 
similar to those that ultimately culminate in irreversible dementia of Alzheimer’s phenotype 
(for review see [34]). Besides β-amyloid peptide and hyperphosphorylated tau protein 
accumulation in postischemic brains, human epidemiological studies indicated a higher 
incidence of dementia (i.e., up to 9-fold) following a few months of ischemic injury [34]. 
Permanent bilateral ligation of the common carotid arteries (2VO) in rats is a suitable 
experimental model to investigate the neurodegeneration and cognitive consequences of 
chronic brain hypoperfusion. Like in human aging and dementia states, the 2VO-animals show 
a progressive loss of hippocampal neurons, which leads to cognitive decline and behavioral 
changes [3]. The usefulness of the 2VO-rat model for the development and testing of 
potentially neuroprotective drugs, against ischemic damage and/or dementia, has been 
emphasized [3]. 
In this work, two analgesic kyotorphin derivatives, KTP-NH2 and IbKTP-NH2, were studied 
regarding their ability to improve cognitive and behavioral functions in 2VO-rat model.  
The “time window of opportunity” for an effective neuroprotective treatment, in relation to 
the timing of the ischemic episode, is an important factor to be considered. Herein, KTP–NH2 
and IbKTP–NH2 were administrated in two periods during the chronic phase of brain 
hypoperfusion: female rats were injected for 7 days in the first week and also in the fourth 
week after the onset of 2VO. This drug administration schedule was chosen taking into 
account the neuropathologic changes in the hippocampal CA1/CA3 subfields over time 
reported in 2VO model, i.e., comprising the periods of negligible neuronal death and when 
hippocampal neuronal injury is obvious [3]. 
 
From our histopathological data, both KTP derivatives were effective in preventing extensive 
neuronal death at the hippocampus. In contrast, in 2VO-animals treated with saline solution 
(2VO-control group) there was a notorious damage at CA1, CA2 and CA3 subfields reflected by 
the disappearance of the well-defined layer of pyramidal neurons (Fig. 3). Moreover, our 
immunofluorescence studies clearly demonstrate the beneficial effects of KTP derivatives on 
CA1 neurons. Loss of neurofilament-L (NFL) proteins may be closely related with the selective 
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vulnerability of CA1 neurons in cerebral ischemia [35]. Chronic hypoperfusion caused a 
significant reduction in the NFL signal in the CA1 subfield (2VO-control group, Fig. 4, Table 1). 
On the other hand, no changes were seen in NFL immunofluorescence for KTP-NH2 and IbKTP-
NH2 groups when compared with sham-control group indicating that KTP derivatives treatment 
afforded neuronal protection.  
Cerebral ischemia triggers reactive astrocytosis, a condition characterized by an increase of 
GFAP levels in astrocytes [3]. In our study there was no evidence of major astrogliosis in 
hippocampal CA1 region after 6 weeks of 2VO surgery. Although astrocytic activation and 
proliferation can be detected in the cortex [3] and hippocampus [2] after 1 week of the 
occlusion, GFAP increase may be not evident until 6 months later [3]. 
 
Rats subjected to global cerebral ischemia may exhibit hypoactivity or hyperactivity or normal 
activity when tested in the open field (for references see [36]). Although ischemic injury may 
affect brain areas related to motor function (i.e, cortex and neocortex regions), there are no 
obvious signs of motor deficits in 2VO-rats [3]. Moreover, variations in environmental 
conditions, namely the level of illumination, may explain in part the different locomotor results 
found in literature [37].  
In our study, the comparable results of the control groups (sham-operated and 2VO) in terms 
of velocity, % of resting and number crossings, suggested that the permanent two-vessel 
occlusion did not impair locomotion performance. This was also observed for the ischemic 
animals treated with KTP-NH2. In fact, when tested in the Y-maze arena all the 2VO-animals 
showed a similar behavior as the sham-operated ones in the total number of arm visits 
(another locomotor activity index, [32]), reinforcing that locomotor activity remained intact in 
2VO-animals and which is also corroborated by other authors [2, 3]. We should emphasize that 
the mild motor impairment observed in the IbKTP-NH2-treated group was not induced by the 
chronic administration of the compound but rather a consequence of the single bolus  dose 
administrated immediately before the open field test. This behavior was already reported by 
us in normal rats (without any type of surgery, and also after 15 min of i.p. injection) and 
seems to be due a synergistic effect of ibuprofen and kyotorphin [20]. 
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Although the motor function was not affected by 2VO surgery, all the female rats subjected to 
bilateral occlusion were more anxious than the sham-controls in the open field, as measured 
by the decreased time spent in the center of the arena.  These results are in agreement with 
previous studies of global ischemia, in which tested animals developed an anxious behavior 
[38]. On the other hand, hippocampus is important in many species-typical behaviors (like 
anxiety), potentially influencing performance in a range of behavioral tests [39]. Previous 
studies indicate that dorsal CA1 lesioned mice are hyperactive upon exposure to a novel 
environment and have spatial working memory impairments in the Y-maze [40]. 
Clinical studies have also shown that neurodegenerative conditions are also associated with 
mood alterations and increased anxiety levels in AD patients [41]. In our study the anxious 
behavior of the operated animals was not affected by the administration of kyotorphin derived 
compounds (Fig. 1), showing that these peptides probably do not possess intrinsic anxiolytic 
properties, and/or did not act on key areas responsible for this behavior.  
Spatial recognition memory of female rats was measured by the two-trial Y-maze test [31, 32]. 
The Y-maze paradigm is based on an innate tendency of rodents to explore a novel 
environment but not on learning a new behavior or rule, allowing to measure behavior 
parameters such as recognition vs. discrimination memory and spatial exploration [31, 32]. 
Rodents typically prefer to investigate a new arm of the maze (unfamiliar) rather than 
returning to one that was previously visited (familiar). Therefore, if memory and novelty-
seeking behavior are not affected, rat females are expected to enter the Novel arm more than 
the Other arm. In our study, although all animals shown to be equally motivated to explore the 
Y-maze (total entries into all arms were similar), their response to novelty inside the maze 
apparatus was not the same. A difference was seen between groups related to the first arm 
choice and percent of time spent in Novel vs Other arms with the 2VO-control group spending 
more time and choosing the Other arm to go first. This indicates that the 2VO surgery induced 
short-term memory deficits, making those females unable to discriminate novelty and 
familiarity. On the other hand, the two KTP-treated groups and the sham-animals chose more 
often first the Novel arm and spent similar time in the Novel vs Other arm. In fact, the 
percentage of animals that entered the Novel arm as the first choice was 100% in both sham- 
and IbKTP-NH2 groups and 60% in KTP-NH2 group.  Since the first choice for Novel arm reflects 
recognition of the unfamiliar arm (discrimination memory), is obvious that the administration 
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over time of IbKTP-NH2 and KTP-NH2 improved the ability of 2VO-animals to distinguish the 
Novel arm from the familiar ones. Therefore, IbKTP-NH2 and KTP-NH2 treatment enhanced 
spatial recognition memory in 2VO animals, with a greater effect of IbKTP-NH2.  
Several studies have found a direct correlation between cerebral hypoperfusion-induced 
memory deficits and hippocampal CA1 neuronal damage [42,43]. Therefore, improved 
memory abilities seen in KTP-treated 2VO animals may be attributed to the neuroprotective 
effects of those peptides on CA1 neurons. 
Moreover, IbKTP-NH2 showed to be more effective in restoring normal cognitive function than 
KTP-NH2. The mechanism underlying this observation seems to involve, at least in part, the 
presence of the NSAID ibuprofen in IbKTP-NH2 derivative, which may attenuate some of the 
neuroinflammatory processes in 2VO-ischemic brain. In rodent models of AD dementia, 
chronic administration of ibuprofen prevents oxidative damage, significantly inhibits amyloid 
formation and deposition, and improves cognitive functions [44,45]. Further studies are 
needed to unveil which are the molecular targets of IbKTP-NH2. 
In conclusion, our experimental findings show that KTP-derivatives improved spatial working 
memory and prevented neuronal damage in hippocampal CA1 subfield induced by chronic 
cerebral hypoperfusion.  
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Figure Legend  
Figure 1- Chemical structures of KTP-NH2 and IbKTP-NH2 
    Tyrosyl residue in pink, Arginyl residue in dark blue, ibuprofenyl residue in green 
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Figure Legend  
Figure 2- Time course of the experiments planned. Animals were divided into groups 
according to the type of surgery and to the injected compound during the two time periods A 
and B: i.e., KTP–NH2 (32.3 mg/kg = 96 µmol/kg), IbKTP–NH2 (24.2 mg/kg = 46 µmol/kg) or 
saline solution (vehicle). 
Abbreviations: i.p., intra-peritoneal; PFA, paraformaldehyde; 2VO, two-vessel occlusion. 
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Figure Legend  
Figure 3 - Representative H&E staining photomicrographs of hippocampal sections from 
sham-operated and 2VO female rats. Histological evaluation was performed in the sixth week 
after the onset of 2VO surgery. (A): images showing ischemic lesion (white area, black arrow) 
in 2VO rat (12.5x magnification); (B): images showing histological changes of the CA1, CA2 and 
CA3 pyramidal cell layers in 2VO-control group (black arrows are pointing at damaged layers) 
(50x magnification).  2VO-control animals showed significant unilateral changes (right or left 
hemisphere) in the histoarchitecture of the cornu ammonis (i.e., CA1, CA2 and CA3) subfields 
reflected by the loss of pyramidal cells layers.These degenerative changes were not observed 
in the two KTP-treated 2VO groups (i.e., KTP-NH2 and IbKTP-NH2). 
Abbreviations: CTR, control; 2VO, two-vessel occlusion; CTR sham, control sham-operated 
animals; DG, dentate gyrus; H&E, hematoxylin and eosin. 
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Figure Legend  
Figure 4- Representative images of double immunofluorescence staining of GFAP and NFL in 
the hippocampal CA1 subfield from sham-operated and 2VO female rats sacrificed six weeks 
after surgery. Neuronal marker NFL is shown in red whereas the astrocytic marker GFAP is 
shown in green. Nuclei are stained blue (Hoechst). 
Upper painels: control groups, sham and 2VO (left and right painel, respectively). Lower 
panels: KTP derivatives treated groups, KTP–NH2 and IbKTP–NH2 (left and right panel, 
respectively) (400x magnification).   
Note a significant decrease in the NFL signal in the 2VO-control group.  
Abbreviations: CTR, control; 2VO, two-vessel occlusion; CTR Sham, control sham-operated 
animals; GFAP, glial fibrillary acidic protein; NFL, neurofilament-L protein. Scale bar= 50 µm 
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Figure Legend  
Figure 5 - Locomotion performance in the open field of KTP-treated rat females, five weeks 
after the onset of 2VO surgery. Animals were subjected to two chronic treatment regimens for 
7 days (single i.p. dose/day of peptides or vehicle) at first week and fourth week after 2VO 
surgery. In the OFT, 2VO-animals were individually placed in the center of the test apparatus 
30 min after being i.p. injected with KTP–NH2 (32.3 mg/kg), IbKTP–NH2 (24.2 mg/kg), or vehicle 
(saline with 5 % DMSO used as a control). Sham-operated animals were injected with the 
vehicle. Behavior was video-recorded for a 5 min time period and data are shown as % time 
spent resting (A), average velocity (B), % time spent in the center of the arena (C) and the 
number of crossings (D). In all experiments, n=5 per group. In (A), (B) and (C): **P< 0.01, ***P< 
0.001 versus control 2VO group and sham-operated group; ##P< 0.01, ###P< 0.001 versus KTP-
NH2, one way ANOVA [P = 0.0003 in (A), P = 0.0027 in (B), P = 0.0001 in (C) and in (D)] followed 
by Tukey’s post test.  
Abbreviations: CTR, control; 2VO, two-vessel occlusion; CTR sham, control sham-operated 
animals. Mean ± SEM for all groups. 
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Figure Legend  
Figure 6 - Cognitive performance in the Y-maze of KTP-treated rat females, five weeks after 
the onset of 2VO surgery. Animals were subjected to two chronic treatment regimens at first 
week and at fourth week after 2VO surgery (single i.p. dose/day during 7 consecutive days): 
KTP–NH2 (32.3 mg/kg), IbKTP–NH2 (24.2 mg/kg), or vehicle (saline with 5 % DMSO used as a 
control). Sham-operated animals were injected with the vehicle. In the Y-maze, animals were 
individually placed in the Start arm of the apparatus and allowed to explore freely the entire 
maze. Behavior was video-monitored for a 5 min time period and data are shown as number of 
total entries (A) and % time spent in the Other and Novel arms (B). In all experiments, n≥4 per 
group. 
In (B): #P< 0.05 versus sham-operated group; *P< 0.05, **P< 0.01 versus control 2VO group, 
one way ANOVA [P =0.0083 for % time in Other arm, P=0.0283 for % time in Novel arm] 
followed by Tukey’s post test. Comparison between % time in Other arm and % time in Novel 
arm: §§ P=0.0028, unpaired two-tailed Student´s test. 
Abbreviations: CTR, control; 2VO, two-vessel occlusion; CTR sham, control sham-operated 
animals. Mean ± SEM for all groups. 
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Table 1 
Quantification of the imunofluorescence signals of GFAP (astrocytic marker) and NFL (neuronal 
marker) in the hippocampal CA1 subfield from sham-operated and 2VO female rats sacrificed 
six weeks after surgery. Measurements were performed bilaterally from 3 to 4 rats per group, 
rendering at least 6 data points per group.  
Data expressed as percentage of the sham-control group (mean ± SEM for all groups). 
***P=0.0004 versus sham-operated group; ##P=0.009, ####P<0.0001 versus control 2VO group, 
unpaired two-tailed Student's t-test.  
 
 
Group GFAP NFL 
CTR 2VO 114 ± 29 45,1 ± 8,8*** 
KTP-NH2 92,7 ± 3,7 119,8 ± 9,3
#### 
IbKTP-NH2 97,4 ± 4,2 109,6 ± 20,2
##  
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Outline and main findings of the experimental work 
 
Previous laboratory work (Ribeiro, 2011a, Ribeiro 2011b) enabled us to obtain results 
with the KTP derivatives that were promising enough to consider a pharmaceutical 
development. After designing and achieving insight over the mechanism of action of 
these new peptides, a characterization of their potential side-effects was missing. This 
characterization is fundamental since most of the drugs, namely opioids, do not thrive 
in the clinical practice due to their side effects (Buenaventura, 2008). 
In our study we had promising kyotorphin amidated derivatives that had 
demonstrated very interesting results: KTP-NH2 and IbKTP-NH2. These drugs were 
selected for their side-effects evaluation in vivo and opioid pathways are involved in 
their mechanism of action, they were at the same time compared with two reference 
opioids commonly used in the clinics: morphine and tramadol. Both KTP-NH2 and 
IbKTP-NH2 showed a strong analgesic effect in the absence of the major side-effects 
associated with classical opioids. 
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Section 4 
Final Conclusions 
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Pain and neurodegeneration are huge clinical problems and even if, through the last 
decades, significant progresses have been made towards designing improved 
therapeutic interventions, considerable efforts are still needed in the search of the 
most appropriate, safe and effective strategies in the management of these conditions. 
Interventions over the vicious cycle between chronic pain and Alzheimer´s disease is of 
extreme importance in order to slow down the whole process and lower the 
associated suffering. The present study was an approach towards that goal, following a 
multi-target combination of clinical and basic science.  
 
The findings shown in the previous chapters gather epidemiologic information and 
molecular analytic results using mass spectrometry, demonstrating the need of a 
biomarker for pain in patients with AD, and that kyotorphin may be one of the links 
between the molecular mechanism of pain and neuroprotection.  
In article 2 we show that pain is underestimated in Alzheimer´s disease patients and 
their caregivers, reinforcing the need for a proper evaluation in the clinical context, 
through the use of validated scales instead of solely relying on the caregiver 
perception. This is an important finding because we are probably undertreating pain in 
this group of patients and untreated pain has several consequences, with symptoms 
such as sadness, anxiety, depression, irritability, sexual dysfunction, disruptions in 
sleeping, eating, mobility, impaired immune function, poor appetite and weight loss 
that are sometimes regarded as symptoms of other conditions and treated 
accordingly. The conclusion of this study is a confirmation that AD patients do not 
valorize their pain complaints, even in moderate stages of the disease and that a 
marker for their pain, would be of the utmost importance.  
The clinical component of this work evolved into the determination of kyotorphin 
levels in the cerebro-spinal fluid of AD patients (article 3), and its correlation with a 
biomarker of the disease (p-Tau protein). We collected and processed samples of CSF 
patients with AD and of healthy ones (individuals who did not have any known 
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neurodegenerative diseases or other serious diseases related to the central nervous 
system). The collaboration with the University Hospital of Santiago de Compostela was 
critical in order to create a mass spectrometry method capable of determining the low 
levels of such a small peptide in a complex matrix such as CSF. A clear negative 
correlation between KTP levels and p-Tau was found. The hypothesis of KTP being a 
molecular link between pain and neurodegeneration is thus valid and new avenues are 
open in clinical research in the largely unexplored domain of pain in patients with 
cognitive impairment. It is equally important to pursue the stimulating hypothesis that 
KTP derivatives of pharmacological interest to fight pain may also have in itself a 
neuroprotective effect, unifying in a single strategy the amelioration of pain and 
neurodegeneration. More important, from the clinical point of view, KTP seems to 
follow the progression of AD. Since KTP may be an important molecule with 
neuroprotective properties (Bocheva, 2004; Nazarenko, 1999), we can hope that KTP 
may be a key-molecule in the link between pain and neurodegeneration. Moreover, it 
could also act as a molecular marker of pain, at least in this group of patients, unable 
to correctly express their suffering. 
With these results in hand, we moved to the next step: evaluation of the effect of 
kyotorphin derivatives in the behavior of an animal model of AD. It must be 
remembered that the compounds KTP-NH2 and IbKTP-NH2 had been previously tested 
(Ribeiro 2011a, Ribeiro 2011b) and were all able to elicit antinociceptive effects in 
animals, following systemic administration (i.p. or oral) at a relatively low dose and 
with no toxicity. KTP-NH2, in particular, showed to be active in several models of acute 
and chronic pain, including neuropathic pain. At the same time, derivatization with 
Ibuprofen granted KTP the ability to cross the BBB. More than being just a lipophilic 
sequence or an anti-inflammatory drug, Ibuprofen appears to work as a delivering 
agent, transporting the KTP across the BBB until its target site. These studies gave new 
insights regarding KTP derivatives mechanism of action: the administration of an 
opioid receptor antagonist (naloxone) previously to KTP peptides injection abolished 
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the nociceptive action of KTP-NH2, while for IbKTP-NH2 the effect was reduced but still 
significant, what suggests that KTP-NH2 is totally dependent on opioid pathways to 
elicit its activity, whereas IbKTP-NH2 has a bivalent mechanism of action: opioid 
dependent and independent. This duality may explain IbKTP-NH2 increased analgesic 
effect when compared to KTP-NH2. Anyway, both act at the CNS, as evidenced in the 
lower nociceptive activity of neurons in the spinal cord. 
In accordance with our previous work, the AD animal model chosen was obtained 
through the bilateral occlusion of the carotid arteries (2 VO model) of female rats. In 
this model, the chronic hypoperfusion to key brain areas leads to neuronal death, 
mainly in the hippocampus and forebrain, therefore mimicking the pattern of AD. 
Moreover, in recent years, investigators have increasingly tended to accept that AD 
may be primarily a vascular disease with neurodegenerative consequences, rather 
than a neurodegenerative disorder with vascular consequences. Two key factors for 
the development of AD have thus been proposed: aging and decreased cerebral 
perfusion. The convergence of them will result in an entity called "critically attained 
threshold of cerebral hypoperfusion” (CATCH). It was proposed that the CATCH leads 
to a distortion of the architecture of the brain capillary, involving the release of nitric 
oxide (NO), which will affect the signaling between the immune, nervous and 
cardiovascular systems. NO is the product of the enzyme nitric oxide synthase (NOS) 
which exists in three isoforms: eNOS (located in the endothelium), nNOS (located in 
neurons), iNOS (inducible in neurons and glial cells after activation by the cytokines) 
(Zhu et al, 2007). Tissues that do not maintain the basal level of NO are more 
predisposed to an amendment of their regulation, extending the excitatory state. 
Thus, the concomitance of advanced age and a risk factor may contribute to vascular 
lesions involving a deficit of NO to such a degree that this could initiate the 
neurodegenerative changes characteristic of AD (De la Torre, 2000). The combination 
of this information found in the literature with our personal experience with 
kyotorphin led us to consider that, given the coincidence of cellular pathways involved, 
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KTP presents important properties that may influence the course of AD: potent 
analgesic, changing currents of calcium, substrate for nNOS, and 
neuromodulator/neuroprotector in key brain areas in Alzheimer's disease. Using 
behavioral tests such as the open field and Y-maze we found that KTP-NH2 and 
Ibuprofen-KTP NH2 were neuroprotective in the hippocampus and improved spatial 
working memory of rats subjected to the 2-VO procedure (article 4). 
The evaluation of possible side effects of the derivatives and the comparison with 
current opioid drugs is shown in the article 5. First of all, we know that the original KTP 
does not bind to opioid receptors (Rackham, 1982) and that morphine and KTP 
derivatives seem to have distinct modes of action. The assay of opioid receptor binding 
clearly established this: KTP-NH2 and IbKTP-NH2 bind weakly to opioid receptors and 
without specificity (Ribeiro 2011a). We showed that common side effects intrinsically 
correlated with binding to opioid receptors as constipation, blood pressure alterations 
and variations in eating pattern were absent from the amidated derivatives. Opioid 
pathways are indirectly involved in KTP peptides mode of action, although in the case 
of IbKTP-NH2, blocking opioid receptors does not suffice to abolish its analgesic 
activity. There are studies showing that the existence of a specific receptor for KTP is 
unlikely (Lopes, 2006) and data support that KTP analgesic activity is probably through 
NO formation leading to the release of met-encephalin (Arima, 1996; Arima,  1997). 
Overall this project helped to build a bridge between two entities with a strong 
epidemiological burden and consequences at personal and social level: pain and 
Alzheimer's disease. It has been shown that kyotorphin and its derivatives are drugs 
with analgesic potential together with diminished side effects.  
On the other hand, as we showed in our animal models, kyotorphin derivatives have 
neuromodulatory and/or neuroprotective properties and KTP itself can serve as a 
biomarker of Alzheimer's disease. In fact our study showed a clear negative correlation 
between KTP levels and p-Tau with KTP seeming to follow the progression of AD. In 
this study, Alzheimer’s disease patients have demonstrated a degree of pain 
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underestimated even by their close caregivers; thus, a biomarker for pain in this group 
of patients is very important.  
On the other hand, the usual age of AD onset coincides with that of the highest 
incidence of pathologies associated with chronic pain, whereby a drug combining 
analgesic and neuromodulatory properties is extremely promising. 
 
In brief, this thesis revealed kyotorphin and its derivatives as potential biomarkers of 
pain in neurodegenerative conditions such as Alzheimer´s disease, as well as drugs 
capable of neuromodulation, opening a door for more extensive studies in this domain 
and raising the hope of fighting pain even in patients incapable of expressing their 
suffering. 
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